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1The work is incorporated in the thesis with the title “SYNTHESIS
AND BIOLOGICAL ACTIVITY OF PHARMACEUTICALLY
IMPORTANT COMPOUNDS” has been described as under.
[A] STUDIES ON PYRAZOLINES
[B] STUDIES ON 1,2,4-TRIAZOLES
[C] STUDIES ON 1,3,4-OXADIAZOLES
[A]    STUDIES ON  PYRAZOLINES
Pyrazoline derivatives are endowed with different therapeutic
property such as antibacterial, analgesic, anthelmintic, antiinflammatory,
antitubercular etc. These valid observation led us to synthesise some novel
pyrazoline derivatives, which have been described as under.
SECTION - I   :   Synthesis and biological evaluation of  1-Aryl-3-
(1’,N-phenyl-3’-p-bromophenyl-pyrazol-4’-yl)-2-propene-1-ones
Type ( I ) R = Aryl
The chalcone derivatives of type (I) have been prepared by the
condensation of 1-N-phenyl-3-p-bromophenyl-4-formyl-pyrazole with




2SECTION - II   :   Synthesis and biological evaluation of  3-Aryl-5-
(1’,N-phenyl-3’-p-bromophenyl-pyrazol-4’-yl)-pyrazolines
Type(II) R=Aryl
Pyrazoline derivatives of type (II)  have been prepared by the
reaction of type (I)  with hydrazine hydrate in appropriate solvent.




Acetyl pyrazoline derivatives of type (III) have been prepared by the

















Phenyl pyrazoline derivatives of type (IV) have been prepared by the
reaction  of type (I)  with phenyl hydrazine in appropriate solvent.
[B] STUDIES ON 1,2,4-TRIAZOLES
Compounds bearing 1,2,4-triazole nucleus shows variety of biological
activity such as antitubercular, amoebicidal, hypnotic, fungicidal, herbicidal,
antiinflammatory, CNS depressant, anticonvulsant, antitumor etc.
Due to the wide range of biological activity, it was contemplated to
synthesise some novel aryl amide, thiadiazole, triazoles, thiadiazepines and
dihydro thiadiazoles bearing triazole nucleus, which have been described as
under.
PART - I    :   STUDIES ON ARYLAMIDES
Substituted arylamide derivatives shows different biological
activity such as antipyratic, analgesic, antiseptic, antiamoebic etc. Some new
arylamide derivatives synthesise with a view to studing their antibacterial






4SECTION - I   :   Synthesis and biological evaluation of 3-Mercapto-
4-N-aroylamino-5-benzhydryl-1,2,4-triazoles
Type (V ) R = Aryl / Alkyl
      Arylamide derivatives of type (V) have been synthesised by
the condensation of 3-mercapto-4,N-amino-5-benzhydryl-1,2,4-triazole with
different aryl acid chloride.
PART - II    :   STUDIES ON 1,3,4-THIADIAZOLO TRIAZOLES
Thiadiazole derivatives have been found to be potent drug in
pharmaceutical and possess a wide spectrum of biological activity such as
antifungal, antibiotic, pesticidal, herbicidal and antithyroid. Some novel
triazoles with 1,3,4-thiadiazole ring are prepared as under.
SECTION - I   :   Synthesis and biological evaluation of 2-Aryl-4-
benzhydryl-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazoles
Type ( VI ) R = Aryl
Substituted triazolo-1,3,4-thiadiazole of type (VI) have been prepared
by condensation of  3-mercapto-4,N-amino-5-benzhydryl-1,2,4-triazole with












5SECTION - II   :   Synthesis and biological evaluation of  2-Aryl-4-
benzhydryl-2,3-dihydro1,2,4-triazolo[3,4-b]-1,3,4-thiadiazoles
Type (VII) R = Aryl
The compounds  o f  type (VI I )  have been prepared by  the
condensation of 3-mercapto-4,N-amino-5-benzhydryl-1,2,4-triazole with
different aromatic aldehydes in presence of p-toluenesulphonic acid.
PART - III    :   STUDIES ON 4-ARYLTRIAZOLES
Different type of 1,2,4-triazole derivatives shows wide range of
b io log ica l  ac t iv i t ies  such as  CNS depressant ,  an t i in f lammatory,
pesticidal, analgesic and antihypertensive. These  valid observation led us
to synthesise some new 1,2,4-triazoles  derivatives,  which have been
described as  under. The starting material is synthesised by two different
methods.
SECTION - I   :   Synthesis and biological evaluation of 3-Mercapto-
4,N-aryl-5-benzhydryl-1,2,4-triazoles
Type ( VIII ) R = Aryl
  The synthesis of triazole derivatives of type (VIII) have been
under taken by  heat ing  o f  potass ium α ,α -d ipheny l  ace tamido











6SECTION - II   :   Synthesis and biological evaluation of 3-Mercapto-
4,N-aryl-5-benzhydryl-1,2,4-triazoles
Type (IX) R = Aryl
Triazoles of type (IX) have been synthesised by chemoselective
heterocyclization of thiosemicarbazides of type (XI) in presence of NaOH.
PART - IV    :   STUDIES ON 1,3,4-THIADIAZEPINES
Thiadiazepine derivatives possess remarkable pharmacological
importance and biological activity such as antifungal, antibacterial,
antiamoebic, anti-HIV and anticancer. We have synthesise some new
1,3,4,thiadiazepines which have been desribed as under.
SECTION - I   :   Synthesis and biological evaluation of 5-
Benzhydryl-1,2,4-triazolo[3,4-b]substituted quinolino[2,3-f]1,3,4-
thiadiazepines
Type(X) R = Aryl
Thiadiazepine derivatives of type (X) have been prepared by the













7[C] STUDIES ON 1,3,4-OXADIAZOLES
Thiosemicarbazides have found their way into almost every branch of
chemistry.  Commercially they are used in dye, photographic film, plastic
and texti le industries. Thiosemicarbazides and their derivatives are
extensively used in medicine especially in the treatment of tuberculosis.
Oxadiazoles are also associated with good therapeutic activity such
as hypnotic,  anaesthetic,  antibacterial ,  anti fungal,  insect icide, and
preservatives.
SECTION - I   :   Synthesis and biological evaluation of  N1-Aryl-
N4-(α,α’-diphenylaceto)-thiosemicarbazides
Type(XI) R=Aryl
Synthesis of thiosemicarbazide of type (XI) have been undertaken by
the  condensat ion o f  d ipheny lace to  hydraz ide  wi th  d i f fe rent  a ry l
isothiocyanates.
SECTION -II   :   Synthesis and biological evaluation of 2-
Arylamino- 5- (α,α’-diphenylmethyl)-1,3,4-oxadiazoles
Type(XII) R=Aryl
Synthesis of arylamino oxadiazoles (XII) have been undertaken by












8SECTION - III   :   Synthesis and biological evaluation of 2-Aryl-5-
(α,α’-diphenylmethyl)-1,3,4-oxadiazoles
Type (XIII) R = Aryl
The oxadizole derivatives of type (XIII) have been prepared by the
condensation of diphenylaceto hydrazide with different aromatic acid in
presence of phosphorous oxychloride.
The constitution of the synthesised product have been characterised
using elemental analysis, infrared and 1H nuclear magnetic resonance
spectroscopy and further supported by mass spectrometry. Purity of all the
compounds have been checked by thin layer chromatography.
in vitro studies on multiple biological activities.
(I) All the compounds have been evaluated for their in vitro biological
assay like antitubercular activity towards a strain of Mycobacterium
tuberculosis H37Rv at a concentration of 6.25 µg/ml  using Rifampin
as standard drug, which have been tested by Tuberculosis Antimicrobial
Acquisition Coordinating Facility (TAACF), alabama, U.S. A.
(II) All the compounds have been also evaluated for their antibacterial
activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of
40µg. The biological activity of the synthesised compounds have been











Medicinal chemistry is important at the outset that drug discovery is not
an unambiguous term in the pharmaceutical R & D world. For example, it can
be defined using either programmatic or organizational approaches (or both),
with several options on each category. Hence, it is important first to understand
this variability and to adopt a specific definition for the purpose of this discussion.
Chemistry related with pharmaceutically important compounds is mainly
divided in two parts. The first, chemotherapy, concerns the treatment of
infections, parasits or maligant diseases by chemical agents, usually substances
that shows selective toxicity towards the pathogen. The other division relates to
diseases of bodily disfunction and the agents employed are mainly compounds
that effect the functioning of enzymes, the transmission of nerve impulses or
the action of hormones on receptors.
The aim of the present study is to capture and harness the already
accumulated experience of the world of pharmaceutical research scientists and
thence rolling forword in research to construct a successful drug design. In doing
this it is necessary to analyse the historical record of drug design because the
progress of drug design is largely driven by instict, intaition and the experience
of pharmaceutical research scientists. So, from the examination and analyses of
the drug design projects of the past, we get a chance to analyse the structures of
a large number of drugs. The study of these drugs and their structures
deconvolute a large amount of information and also give us an intaitive and
inspirational push towards our research for successful drug design.
9
Heterocyclic compounds shows vital role in the field of pharmaceutical.
Heterocyclic compounds are used because they have a specific clinical reactivity,
for example epoxides, aziridines and β-lactams. The introduction of heterocyclic
group into drugs may affect their physical properties, for example the dissociation
constants of sulpha drugs or modify their patterns of absorption, metabolism or
toxicity.
There are many such natural products which have come in human
observation since very ancient times for the treatment & curing of human
illnesses. Later in the modern times, such substances and products have been
isolated by modern scientific & medicinal research. Having been purified,
modified and improved, these substances have come out brilliantly as medicinal
drugs i.e. the chinese drug "Mauhang" which has been known to be used as
medicine since last 5000 years but its active principle-ephidrin was isolated only
as late as 1887.
A large number of important drugs have been introduced during the period
of 1940 to 1960. This period is known as the "Golden Period" of new drug
discovery. Thus starting from 1933, the first antibacterial drug 'prontosil' leading,
and various other sulpha drugs following, such as: 1940-penicillin; 1945-
chloroquine, an antimalarial; 1950-methyldopa, antidiabetic; 1960-semi
synthetic penicillin, antibacterial; 1965-trimethoprim, antimicrobial; 1967-
disodium chemoglycoate, antiallergic; 1972-cimetidine H2-antagonist; 1975-
verapamil, calcium antagonist; 1981-captopril, antihypertensive. These are some
specific examples representing new therapeutics.
Taking in view the applicability of heterocyclic compounds, we have
undertaken the preparation of pyrazoline, 1,2,4-triazole and 1,3,4-oxadiazole
derivatives. The placement of a wide variety of substituents on these nuclei
have been designed in order to evaluate the synthesised products for their
10
pharmacological profile against several strains of bacteria and fungi.
AIMS AND OBJECTIVES
The aim and objectives of the present investigation is
1. To generate several chalcones, 1H-pyrazolines, acetyl pyrazolines and
phenyl pyrazolines.
2. to generate several arylamides, 1,3,4-thiadiazoles,4-aryltriazoles, 1,3,4-
thiadiazepines bearing 1,2,4-triazole moiety.
3. To generate several 1,3,4-oxadiazoles.
4. To characterize these products for structure elucidation using spectroscopic
techniques like IR, PMR and Mass spectral studies.
5. To check purity of all compounds using thin layer chromatography.
6. To evaluate these new products for better drug potential against different
strains of bacteria and fungi.
7. Selcted compounds have been sent to "Tuberculosis Antimicrobial
Acquisition and Co-ordinating Facility (TAACF), Southern Research Institute






Amongst nitrogen containing five membered heterocycles, Pyrazolines have
proved to be the most usefull framework for biological activities. Pyrazolines
have attracted attention of medicinal chemists for both with regard to heterocyclic
chemistry and the pharmacological activity associated with them. The chemistry
of pyrazoline was reviewed by Jorbe in 1967, which have been studied
extensively for their biodynamic behaviour1 and industrial applications2.
Pyrazoline has three possible tautomeric structures, but the structure shown is
the most stable, which can be prepared by hydrazine hydrate and acrolein.
SYNTHETIC ASPECT
Different methods for the preparat ion of 2-pyrazol ine derivat ives
documented in literature are as follows.
1. The most common procedure for the synthesis of 2-pyrazolines is the
reaction of an aliphatic  or aromatic hydrazine with α,β-unsaturated
carbonyl compounds.

























3. 2-pyrazolines can be constructed by the cyclo condensation of chalcones
with hydrazine hydrate3.
4. 2-pyrazolines can be prepared by condensation of chalcone dibromide with
hydrazines4.
5. 2-pyrazoline derivatives can be prepared by intramolecular 1,3-di polar
addition of diarylnitrilimines generated from 2,5-di aryl tetrazoles5.
6. Epoxidation of chalcones have epoxy ketones which reacted with hydrazine
and phenyl hydrazine to give pyrazolines6.
7. Dipolar cycloaddition of nitrilimines of dimethyl fumarate, fumaronitrile
and the N-aryl maleimides yields the corresponding pyrazolines7.
One pot synthesis of some pyrazolines in dry media under microwave
irradiation investigated by B. Gyassi et al.8 Further more S. Paul et al.9 and
Dandia  Anshu10 have also described the microwave assisted syntehsis  of 2-
pyrazolines.
REACTION MECHANISM.
The following mechanism seems to be operable for the condensation of


















































Nucleophillic attack by hydrazine at the β-carbon of the α,β-unsaturated
carbonyl system forms species (II), in which the negative charge is mainly
accommodated by the electronegative oxygen atom. Proton transfer from the
nitrogen to oxygen produces an intermediate end which simultaneously ketonises
to ketoamine (III). Another intramolecular nucleophillic attack by the primary
amino group of ketoamine on its carbonyl carbon followed by proton transfer
from nitrogen to oxygen leads  ultimately to hydroxyl amine (IV). The later with
a hydroxy group and amine group on the same carbon lose water easily to yield
the pyrazolines.
THERAPEUTIC IMPORTANCE














B. Shivarama Holla et al.24 have synthesised pyrazolines (I) and tested
them as antibacterial agents. S. S. Sonarc25 have synthesised-3-(2-acetoxy-4-
methoxyphenyl)-5-(substituted phenyl)-pyrazoline as antimicrobial agents. G.
N. Mishirika et al.26 have also prepared 2-pyrazoline derivatives of salicylic
acid possesing antimicrobial properties. Tuntawy, Atif et al.27 have patented
pyrazolines as antibacterial agents.
Pyrazolines... 14
Nisha Singh and co-workers28 have synthesised 1-acetyl pyrazolines (II)
and reported them as potent pesticides and fungicides. Nugent Richard et al.29
have investigated pyrazolines bis phosphonate as novel antiinflammatory and
antiarthritic agents.
More over F. Manna and co-workers30 have described 1H-pyrazolines and
its derivatives as potent antiinflammatory, analgesic and antipyratic agents.
Heetika Malik et al.31 have prepared 1H- pyrazoline (III) derivatives and
reported them as pesticides. Udupi R. H. and Bhat A. R.32 have reported the






















E. Palska et al.33 have prepared 3,5-diphenyl-2-pyrazoline derivatives (IV)
and screened them as antidepressant agents.
T. M. Stivenson et al.34 have also investigated N-substituted pyrazoline as
insecticidal agents. Shulabh Sharma et al.35 have synthesised some pyrazoline
derivatives (V) of anthranilic acid and reported them as antiinflammatory agents.
B. Shivarama Holla et al.36 have screened pyrazolines as antibacterial agents.
K. Mogilaiah and G. Raman Sudhakar37 have also reported pyrazolines as
antibacterial agents.
CONTRIBUTION FROM OUR LABORATORY
Jatin Upadhyay et al.38 have synthesised 1-acetyl-4,5 dihydro-5-(4-
hydroxy-3-methoxyphenyl)-3-(4-phenyl sulphonamidophenyl)-1H-pyrazoline
and other derivatives for their antimicrobial activity. Vikani and co-workers39
have synthesised pyrazoline derivatives from arsanilic acid for their antimicrobial
activity against different strains of bacteria and fungi. P. Patel et al.40 have
reported some novel pyrazoline derivatives as antimicrobial agents. P. M. Patel
and A. R. Parikh41 have investigated 3-(3'-bromo-4'-acetamidophenyl)-5-aryl-
1H/1-acetyl-2-pyrazolines. Akhil H. Bhatt and H. H. Parekh et al.42 have shown
moderate antimicrobial activity of some pyrazoline derivatives. N. S. Shah and
A. R. Parikh et al.43 have synthesised pyrazolines and reported them as potent























activity of pyrazolines. Many other pyrazolines have been reported by A. R.
Parikh, H. H. Parekh and co-workers having good biological activity in the
literarture.
More recently Z. Brzozowski et al.45 have synthesised some pyrazolines
and reported them as antitumor agents. Malhotra et al.46 have investigated
pyrazolines as cardiovascular agents. Mourer Fritz and coworkers47 have
synthesised pyrazolines used as pesticidal coating material agents. Shrinivas et
al.48 have investigated pyrazoline derivatives as antimicrobial agents.
Led by these considerations, several derivatives of chalcones and 2-
pyrazolines bearing 1,N-phenyl-3-p-bromophenyl-4-formyl-pyrazole nucleus
have been investigated and described as under.
SECTION-I : SYNTHESIS AND BIOLOGICAL EVALUATION OF 1-
A RY L - 3 - ( 1 ' , N -P H E N Y L - 3 ' - p -B R O M O P H E N Y L
PYRAZOL-4'-YL)-2-PROPENE-1-ONES
SECTION-II : SYNTHESIS AND BIOLOGICAL EVALUATION OF 3-
ARYL-5 - (1 ' ,N -PHENYL-3 ' - p -BROMOPHENYL-
PYRAZOL-4'-YL)-PYRAZOLINES
SECTION-III : SYNTHESIS AND BIOLOGICAL EVALUATION OF
1 , N -AC E T Y L - 3 -A RY L - 5 - ( 1 ' , N -P H E N Y L - 3 ' - p -
BROMOPHENYL-PYRAZOL-4'-YL)-PYRAZOLINES
SECTION-IV : SYNTHESIS AND BIOLOGICAL EVALUATION OF




SYNTHESIS AND BIOLOGICAL EVALUATION OF 1-ARYL-3-(1',N-
PHENYL-3'-p-BROMOPHENYL-PYRAZOL-4'-YL)-2-PROPENE-1-ONES
During the past years, considerable evidence has been accumulated to
demonstrate the efficiency of chalcones in including variety of therapeutic
activities. To further assess the potential of such a class of compounds as
antibacterial and antifungal agents, a series of chalcones of type (I) have been
synthesised by the condensation of 1,N-phenyl-3-p-bromophenyl-4-formyl-
pyrazole with different aryl ketones as shown in reaction scheme (I).
The constitution of the synthesised products have been characterised using
elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy
and further supported by mass spectrometry. In mass spectrometry the m/z value
indicated the molecular weight. i.e. when R=ρ-Methoxy phenyl =459, m/z=
461 (m+2).
All the compounds have been also evaluated for their antibacterial activity
towards Gram positive and Gram negative bacterial strains and antifungal activity
towards Aspergillus niger at a concentration of 40 µg/ml. The biological activity
of the synthesised compounds have been compared with standard drugs. Some
compounds have been found to have good activity. The details have been cited






R = ArylType (I)
18
REACTION SCHEME


























IR SPECTRAL STUDY OF 1-p -METHOXYPHENYL-3- (1 ' ,N-PHENYL-3 ' -p -
BROMOPHENYL-PYRAZOL-4'-YL)-2-PROPENE-1-ONE
I
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C–H str. (asym.) 2989.5 2975-2950 399
-CH3 C–H str. (sym.) 2885.3 2880-2860 ''
C–H def. (asym.) 1460.9 1470-1435 ''
C-H def. (sym.) 1375.2 1385-1370 ''
 Aromatic C–H str. 3062.7 1380-3030 400
C=C str. 1515.9 1585-1430 ''
C–H i.p.def. 1093.6 1125-1090 "
1024.1 1070-1000 ''
C-H o.o.p. def. 829.3 835-810 "
Pyrazole C=N str. 1591.2 1612-1593 "
C–N str. 1164.9 1420-1020 ''
N-N str. 1002.9 1050-1010 "
C-Br str. 559.3 600-500 "
Ether C–O-C str. (asym.) 1265.2 1275-1200 399
C-O-C str. (sym.) 927.7 1075-1020 "
Chalcone C=O str. 1662.5 1690-1665 401
































PMR SPECTRAL STUDY OF 1-(p-METHOXYPHENYL)-3-(1 ' ,N-PHENYL-3 ' -p-
BROMOPHENYL-PYRAZOL-4'-YL)-2-PROPENE-1-ONE
Internal Standard : TMS
Solvent : CDCl3
Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position J value Relative No. Multiplicity Inference
No. (δ ppm) Hz of Protons
1 3.87 - 3H singlet Ar-OCH3
2 7.03 Hfg=7.2 2H doublet Ar-H,hh'
3 7.29 Hzy=15 1H doublet Ar-H, Z(vinyl)
4 7.37 Hda=6.6 1H triplet Ar-H, d
5 7.48 Hih=8.7 2H doublet Ar-H, ff'
6 7.51 Hbd=6.3 1H doublet Ar-H, b
7 7.63 Hgf=7.2 3H multiplet Ar-H, gg'
+Ar-H, a
8 7.79 Hhi=8.1 2H doublet Ar-H, ii'
9 7.82 - 2H multiplet Ar-H, c,e
10 7.89 Hyz=15.6 1H doublet Ar-H,Y (Vinyl)






































































































































































Gram Positive bacteria : Staphylococcus aureus
Bacillus megaterium
Gram negative bacterial : Proteus vulgaris
Escherichia coli
Fungi : Aspergillus niger
Concentration : 40µg.
Solvent : Dimethyl formamide.
Standard drugs : Amipicillin, Amoxicillin,
Norfloxacin, Penicillin, Greseofulvin.
The antimicrobial activity was compared with standard drug viz Ampicillin,
Amoxicillin, Norfloxacin, Penicillin and antifungal activity was compared with
viz Greseofulvin. The inhibition zones measured in mm.
ANTITUBERCULAR ACTIVITY
The antitubercular evaluation of the compounds was carried out at
Tuberculosis Antimicrobial Acquisition and Co-ordinating Facility (TAACF) U.S.A.
Method :  BACTEC 460 Radiometric System.
Bacteria : Mycobacterium tuberculosis H37Rv
Concentration : 6.25 µg/ml.
Standard drug : Rifampin
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL EVALUATION OF 1-ARYL-3-(1',N-
PHENYL-3'-p-BROMOPHENYL-PYRAZOL-4'-YL)-2-PROPENE-1-ONES
(A) Synthesis of N-Phenylamino-α-methyl-p-bromophenyl azomethine
A mixture of phenylhydrazine (1.08g, 0.01m) and p-bromoacetophenone
(1.98g, 0.01m) in absolute ethanol was refluxed in water bath for 12 hrs. in
presence of glacial acetic acid (1ml). The crude product was crystallised from
absolute alcohol. Yield 2.56g, 89%, m.p. 39oC. (C14H13BrN2; required: C,
58.15; H, 4.53; N, 9.69; found : C, 58.13; H, 4.50; N, 9.66%)
(B) Synthesis of 1-N-Phenyl-3-p-bromophenyl-4-formyl-pyrazole
N-phenylamino-α-methyl-p-bromophenyl azomethine (1.15g, 0.004M) was
added to Vilsemeier-Haack reagent [prepared by dropwise addition of POCl3
(1.2ml) in ice cooled DMF (10 ml)] and refluxed for 5 hrs. The reaction mixture
was poured onto crushed ice and followed by neutralization using sodium
bicarbonate. Crude product was isolated and crystallised from ethanol. Yield
2.47g, 74%, m.p. 186oC. (C16H11BrN2O; required: C, 58.74; H, 3.39, N, 8.56;
found C, 58.70; H, 3.37; N, 8.55%).
TLC Solvent System : Acetone : Benzene (1 : 9)
(C) Synthesis of 1-(p-Methoxyphenyl)-3-(1',N-phenyl-3'-p-bromophenyl-
pyrazol-4'-yl)-2-propene-1,ones
To a well stirred solution of 1,N-phenyl-3-p-bromophenyl-4-formyl-pyrazole
(3.27g, 0.01M), and p-methoxy acetophenone (1.50 g, 0.01 M) in ethanol (25
ml), 40% NaOH added till the solution was basic. The reaction mixtrue was
stirred for 24 hrs. The contents were poured onto ice, acidified, filtered and
crystallised from ethanol. Yield 3.71g, 81% m.p. 129oC. (C25H19BrN2O2;
required : C, 65.37: H, 4.17; N, 7.36; found : C, 65.38; H, 4.15; N, 7.31%).
TLC Solvent System : Acetone : Benzene (2 : 8)
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Similarly other 1-aryl-3-(1',N-phenyl-3'-p-bromophenyl-pyrazol-4'-yl)-2-
propene-1-ones were prepared. The physical data are recorded in Table No. 1.
(D) Antimicrobial activity of 1-Aryl-3-(1',N-phenyl)-3'-p-bromophenyl-
pyrazol-4'-yl)-2-propene-1-ones
Antimicrobial activity was carried out by cup-plate diffusion method49
which has been described as under.
(I) Antibacterial activity
The purified products were screened for their antibacterial activity. The
nutrient agar broth prepared by the usual method, was inoculated aseptically
with 0.5 ml of 24 hrs. old subcultures of B. megaterium, S. aureus, E. coli,
P. vulgaris in separate conical flasks at 40-50oC and mixed well by gently
shaking. About 25ml content of the flask were poured and evenly spreaded in a
petridish (13cm in diameter) and allowed to set for 2 hrs. The cups 10 mm in
diameter were formed by the help of borrer in agar medium and filled with
0.04ml (40µg) solution of sample in DMF.
The plates were incubated at 37oC for 24 hrs. and the control was also
maintained with 0.04 ml of DMF in a similar manner and the zones of inhibition
of the bacterial growth were meusured in millimeter and are recorded in
Graphical Chart No. 1.
(II) Antifungal Activity
A. niger was employed for testing antifungal activity using cup-plate
method. The culture  was maintained on sabouraud's agar slants. Sterilised
subouraud's agar medium was inoculated with 72 hrs. old 0.5 ml suspension of
fungal spores in seperate flask. About 25 ml of the inoculated medium was
evenly spreaded in a petridish and allowed to set for two hrs. The cups (10 mm
in diameter) were punched. The plates were incubated at 30oC for 48 hrs. After
the completion of incubation period, the zones of inhibition of growth in the
form of diameter in mm was measured. Along the test solution in each petridish
one cup was filled up with solvent which act as control. The zones of inhibition
are recorded in Graphical Chart No. 1
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ANTITUBERCULAR ACTIVITY
The antitubercular evaluation of the compounds was carried out at
Tuberculosis Antimicrobial Acquisition and Co-ordinating Facility (TAACF),
U.S.A. Primary screening of the compounds for antitubercular activity have been
conducted at 6.25 µg/ml towards Mycobacterium Tuberculosis H37Rv in BACTEC
12B medium using the BACTEC 460 radiometric system. The compounds
demostrating atleast > 90% inhibition in the primary screen have been retested
at lower Mycobacterium Tuberculosis H37Rv to determined the actual minimum
inhibitory concentration (MIC) in th BACTEC 460.
The antitubercular activity data have been compared with standard drug




























1a C6H5- C24H17BrN2O 429 143 0.614 78 7.99 7.94
1b 4-Br-C6H4- C24H16Br2N2O 508 162 0.718 64 6.53 6.49
1c 4-Cl-C6H4- C24H16BrClN2O 464 167 0.691 81 7.28 7.23
1d 4-F-C6H4- C24H16BrFN2O 447 158 0.531 88 7.60 7.53
1e 4-NH2-C6H4- C24H18BrN3O 444 126 0.842 69 11.50 11.47
1f 3-NH2-C6H4- C24H18BrN3O 444 144 0.780 82 11.50 10.48
1g 4-NO2-C6H4- C24H16BrN3O3 474 137 0.619 87 10.63 10.58
1h 3-NO2-C6H4- C24H16BrN3O3 474 162 0.871 76 10.63 10.61
1i 4-CH3-C6H4- C25H19BrN2O 443 173 0.568 85 7.69 7.66
1j 4-OCH3-C6H4- C25H19BrN2O2 459 129 0.714 79 7.36 7.31
1k 4-OH-C6H4- C24H17BrN2O2 445 159 0.669 74 7.65 7.64
1l 2-OH-C6H4- C24H17BrN2O2 445 173 0.723 86 7.65 7.63


























B. mega 17 14 19 21 13 11 16 11 20 13 15 18 23 22 24 25 0
S. aureus 15 18 12 16 14 14 16 14 20 11 13 14 22 23 17 24 0
E. coli 14 16 19 13 15 12 16 17 20 17 14 17 21 21 23 19 0
P. vulgaris 14 12 17 11 12 10 12 13 16 14 12 11 15 18 17 20 0
A.niger 14 17 17 17 14 13 17 16 19 21 16 15 0 0 0 0 25












GRAPHICAL CHART NO. 1 :  1-ARYL-3-(1’,N-PHENYL-3’-p-BROMOPHENYL-PYRAZOL-4’-YL)-2-PROPENE-1-ONES
COMPARATIVE STUDY OF ANTIMICROBIAL ACTIVITY WITH KNOWN ANTIBIOTICS
[A]
Section - I : Antimicrobial activity of 1-Aryl-3-(1’,N-phenyl-3’-p-bromophenyl-pyrazol-4’-yl)-2-propene-
1-ones
1d (21) 1b (18) 1c (19) 1c (17) 1i (19)
1i (20) 1d (16) 1i (20) 1i (16) 1j (21)
1g (16)
1i (20)
Ampicillin 23 22 21 15 -
Amoxicillin 22 23 21 18 -
Norfloxacin 24 17 23 17 -
Penicillin 25 24 19 20 -
Greseofulvin - - - - 25
B. mega S. aureus E. coli P. vulgaris A. niger
Antifungal activity
Zone of inhibition in m.m.
Antibacterial activity




SYNTHESIS AND BIOLOGICAL EVALUATION OF 3-ARYL-5-(1',N-
PHENYL-3'-p-BROMOPHENYL-PYRAZOL-4'-YL)-PYRAZOLINES
Pyrazolines play a vital role owing of their wide range to pharmacological
activity and with an aim to getting better drug, it was considered worthwhile to
synthesise some new pyrazolines. The preparation of 3-Aryl-5-(1',N-phenyl-3'-
p-bromophenyl-pyrazol-4'-yl)-pyrazolines (II) have been under taken by
cyclocondensation of chalcones of type (I) with hydrazine hydrate.
The constitution of the synthesised products have been characterised using
elemental analyses, infra red and 1H nuclear magnetic resonance spectroscopy
and further supported by mass spectrometry. In mass spectrometry the m/z value
indicate the molecular weight, i.e. when R=p-Methoxy phenyl =473, m/z=473.
All the compounds have been evaluated for their antibacterial activity
towards Gram positive and Gram negative bacterial strains and antifungal activity
towards Aspergillus niger at a concentration of 40 µg/ml. The biological activity
of the synthesised compounds have been compared with standard drugs. Some
compounds have been found to have good activity as compared to known




























TYPE (II) R = Aryl
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IR SPECTRAL STUDY OF 3-PHENYL-5-(1' ,N-PHENYL-3'-ρ -BROMOPHENYL-
PYRAZOL-4'-YL)-PYRAZOLINE
I
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
 Aromatic C–H str. 3047.3 3080-3030 400
C=C str. 1477.4 1585-1430 ''
C–H i.p.def. 1153.4 1125-1090 "
1018.3 1070-1000 ''
C-H o.o.p. def. 840.9 835-810 "
Pyrazole C=N str. 1600.8 1612-1593 "
C–N str. 1292.2 1420-1020 ''
N-N str. 983.6 1050-1010 "
C-Br str. 565.1 600-500 "
Pyrazoline N-H str. 3413.8 3400-3200 401,402



































PMR SPECTRAL STUDY OF 3-(p-METHOXYPHENYL)-5-(1 ' ,N-PHENYL-3 ' -p-
BROMOPHENYL-PYRAZOL-4'-YL)-PYRAZOLINE
Internal Standard : TMS
Solvent : CDCl3
Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position J value Relative No. Multiplicity Inference
No. (δ ppm) Hz of Protons
1 3.03 - 1H doublet-doublet Pyrazoline
-CHy
2 3.42 - 1H doublet-doublet Pyrazoline
-CHz
3 3.85 - 3H singlet Ar-OCH3
4 5.14 - 1H doublet-doublet Pyrazoline
-CHx
5 6.99 Jfg=8.7 2H doublet Ar-H, hh'
6 7.26 - 1H multiplet Ar-H, d
7 7.42 Jih=8.1 2H doublet Ar-H, ff'
8 7.51 - 4H multiplet Ar-H, a,b,c,e
9 7.62 Jgf=8.7 2H doublet Ar-H, gg'
10 7.70 Jhi=7.8 2H doublet Ar-H, ii'










































































































































































SYNTHESIS AND BIOLOGICAL EVALUATION OF 3-ARYL-5-(1',N-
PHENYL-3'-p-BROMOPHENYL-PYRAZOL-4'-YL)-PYRAZOLINES
(A) Synthesis of 1-Aryl-3-(1',N-phenyl-3'-p-bromophenyl-pyrazol-4'-yl)-
2-propene-1-ones
See [A] Section-I (C)
(B) Synthesis of 3-p-Methoxyphenyl-5-(1',N-phenyl-3'-p-bromophenyl-
pyrazol-4'-yl)-pyrazolines
A mixture of 1-p-methoxyphenyl-3-(1',N-phenyl-3'-p-bromophenyl-pyrazol-
4'-yl)-2-propene-1-ones (4.59g, 0.01M) in ethanol (25 ml) and hydrazine hydrate
(0.5 g, 0.01M) was refluxed for 8 hrs. The porduct was isolated and crystallised
from ethanol. Yield 3.26g, 69%, m.p. 146oC. (C25H21BrN4O; required: C, 63.4;
H, 4.47; N, 14.20; found : C, 63.1; H, 4.43; N, 14.17%.)
TLC Solvent System : Acetone : Benzene (4 : 6)
Similarly other pyrazolines were synthesised. The physical data are recorded
in Table No. 2.
(C) Antimicrobial activity of 3-Aryl-5-(1',N-phenyl-3'-p-bromophenyl-
pyrazol-4'-yl)-pyrazolines
Antimicrobial testing was carried out as described in [A] Section-I (D). The
zone of inhibition of test solutions are recorded in Graphical Chart No. 2.
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2a C6H5- C24H19BrN4 443 127 0.591 77 15.37 15.33
2b 4-Br-C6H4- C24H18Br2N4 522 107 0.887 89 12.64 12.63
2c 4-Cl-C6H4- C24H18BrClN4 478 182 0.719 71 14.05 14.07
2d 4-F-C6H4- C24H18BrFN4 461 156 0.643 74 14.65 14.62
2e 4-NH2-C6H4- C24H20BrN5 458 137 0.729 82 18.46 18.42
2f 3-NH2-C6H4- C24H20BrN5 458 188 0.578 77 18.46 18.45
2g 4-NO2-C6H4- C24H18BrN5O2 488 122 0.872 69 17.10 17.07
2h 3-NO2-C6H4- C24H18BrN5O2 488 119 0.692 81 17.10 17.06
2i 4-CH3-C6H4- C25H21BrN4 457 133 0.810 78 14.80 14.76
2j 4-OCH3-C6H4- C25H21BrN4O 473 146 0.735 72 14.20 14.17
2k 4-OH-C6H4- C24H19BrN4O 459 164 0.538 83 14.73 14.61



























*TLC Solvent System : Acetone : Benzene (4 : 6)
4
2
























B. mega 14 16 19 17 13 18 16 21 17 14 15 17 23 22 24 25 0
S. aureus 13 18 16 12 15 11 13 14 12 10 17 15 22 23 17 24 0
E. coli 17 15 16 20 14 15 18 13 12 15 17 15 21 21 23 19 0
P. vulgaris 12 13 17 11 15 10 13 11 14 12 10 16 15 18 17 20 0
A.niger 18 16 18 20 17 14 15 17 20 17 18 19 0 0 0 0 25












COMPARATIVE STUDY OF ANTIMICROBIAL ACTIVITY WITH KNOWN ANTIBIOTICS
[A]
Section - II : Antimicrobial activity of 3-Aryl-5-(1’,N-phenyl-3’-p-bromophenyl-pyrazol-4’-yl)-pyrazolines
2c (19) 2b (18) 2d (20) 2c (17) 2d (20)
2h (21) 2c (16) 2g (18) 2e (15) 2i (20)
2k (17) 2l (16) 2l (19)
Ampicillin 23 22 21 15 -
Amoxicillin 22 23 21 18 -
Norfloxacin 24 17 23 17 -
Penicillin 25 24 19 20 -
Greseofulvin - - - - 25
B. mega S. aureus E. coli P. vulgaris A. niger
Antifungal activity
Zone of inhibition in m.m.
Antibacterial activity




SYNTHESIS AND BIOLOGICAL EVALUATION OF 1,N-ACETYL-3-ARYL-
5-(1',N-PHENYL-3'-p-BROMOPHENYL-PYRAZOL-4'-YL)-PYRAZOLINES
1-Acetyl pyrazoline have been found to be associated with diverse biological
activities. These findings prompted us to synthesise some representative
pyrazoline derivatives of the type (III) coupled with pyrazole nucleus possesing
better biological activity, which have been synthesised by the condensation of
chalcone of type (I) with hydrazine hydrate in acetic acid.
The constitution of the synthesised products have been characterised using
elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy
and further supported by mass spectrometry. In mass spectrometry the m/z value
indicates the molecular weight, i.e. when R=p-Methoxy phenyl =515, m/z =515.
The products have been screened for their in vitro biological assay like
antibacterial towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml.
The biological activity of the synthesised compounds have been compared with
standard drugs. Some compounds have been found to have good activity as








R = ArylType (III)
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REACTION SCHEME























IR SPECTRAL STUDY OF 1,N-ACETYL-3-p-AMINOPHENYL-5-(1',N-PHENYL-3'-p-
BROMOPHENYL PYRAZOL-4'-YL)-PYRAZOLINE
I
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
 Alkane C–H str. (asym.) 2964.4 2975-2950 399
-CH3 C-H str. (sym.) 2840.9 2880-2860 ''
C–H def. (asym.) 1442.7 1470-1435 "
C-H def. (sym.) 1363.6 1385-1370 ''
 Aromatic C–H str. 3051.2 3080-3030 400
C=C str. 1510.2 1585-1430 ''
C–H i.p.def. 1064.6 1125-1090 "
991.3 1070-1000 ''
C-H o.o.p. def. 827.4 835-810 "
Pyrazole C=N str. 1604.7 1612-1593 "
C–N str. 1253.6 1420-1020 ''
N-N str. 1020.3 1050-1010 "
C-Br str. 561.2 600-500 "
Pyrazoline N-COCH3 str. 1660.6 1660-1600 401,402
Primary amine N-H str. 3450.4 -3400 399
N-H def. 1548.7 1650-1590 "








































PMR SPECTRAL STUDY OF 1,N-ACETYL-3-p-METHOXYPHENYL-5-(1',N-PHENYL-3'-
p-BROMOPHENYL-PYRAZOL-4'-YL)-PYRAZOLINE
Internal Standard : TMS
Solvent : CDCl3
Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position J value Relative No. Multiplicity Inference
No. (δ ppm) Hz of Protons
1 2.43 - 3H singlet Ar-CO-CH3
2 3.04 - 1H doublet-doublet Pyrazoline-CHy
3 3.54 - 1H doublet-doublet Pyrazoline-CHz
4 3.80 - 3H singlet Ar-OCH3
5 5.85 - 1H doublet-doublet Pyrazoline-CHx
6 6.915 Hfg=8.7 2H doublet Ar-H, hh'
7 7.24 - 1H multiplet Ar-H, d
8 7.38 Hih=8.1 2H doublet Ar-H, ff'
9 7.50 - 4H multiplet Ar-H, a,b,c,e
10 7.63 Hgf=8.7 2H doublet Ar-H, gg'
11 7.67 Hhi=7.9 2H doublet Ar-H, ii'































































































































































SYNTHESIS AND BIOLOGICAL EVALUATION OF 1,N-ACETYL-3-ARYL-
5-(1',N-PHENYL-3'-p-BROMOPHENYL-PYRAZOL-4'-YL)-PYRAZOLINES
(A) Synthesis of 1-Aryl-3-(1',N-phenyl-3'-p-bromophenyl-pyrazol-4'-yl)-
2-propene-1-ones
See [A] Section-I (C)
(B) Synthesis of 1,N-Acetyl-3-(p-methoxyphenyl)-5-(1',N-phenyl-3'-p-
bromophenyl-pyrazol-4'-yl)-pyrazolines
A mixture of 1-p-methoxyphenyl-3-(1',N-phenyl-3'-p-bromophenyl-pyrazol-
4'-yl)-2-propene-1-ones (4.59 g, 0.01M) in acetic acid (20 ml) and hydrazine
hydrate (0.5 g, 0.01 M) was refluxed for 10 hrs. The content was poured onto
crushed ice. Product was isolated and crystallised from ethanol. Yield 3.81g,
74%, m.p. 181oC. (C27H23BrN4O2; required: C, 62.9; H, 4.5; N, 12.84; found
: C, 62.3; H, 4.4; N, 12.81%).
TLC Solvent System : Acetone : Benzene (3 : 7)
Similarly other 1-acetyl pyrazolines were synthesised. The physical data
are recorded in Table No. 3.
(C) Antimicrobial activity of 1,N-Acetyl-3-Aryl-5-(1',N-phenyl-3'-p-
bromophenyl-pyrazol-4'-yl)-pyrazolines
Antimicrobial testing was carried out as described in [A] Section-I(D). The
zone of inhibition of test solutions are recorded in Graphical Chart No. 3.
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3a C6H5- C26H21BrN4O 485 183 0.837 82 13.78 13.73
3b 4-Br-C6H4- C26H20Br2N4O 564 179 0.619 66 11.54 11.53
3c 4-Cl-C6H4- C26H20BrClN4O 520 210 0.742 79 12.71 12.68
3d 4-F-C6H4- C26H20BrFN4O 503 172 0.889 86 13.20 13.22
3e 4-NH2-C6H4- C26H22BrN5O 500 167 0.571 62 16.62 16.60
3f 3-NH2-C6H4- C26H22BrN5O 500 158 0.773 73 16.62 16.57
3g 4-NO2-C6H4- C26H20BrN5O3 530 170 0.839 89 15.51 15.50
3h 3-NO2-C6H4- C26H20BrN5O3 530 129 0.605 76 15.51 15.51
3i 4-CH3-C6H4- C27H23BrN4O 499 146 0.576 70 13.32 13.28
3j 4-OCH3-C6H4- C27H23BrN4O2 515 181 0.792 74 12.84 12.81
3k 4-OH-C6H4- C26H21BrN4O2 501 133 0.651 80 13.26 13.23





















































B. mega 17 14 19 15 13 12 21 16 17 20 17 14 23 22 24 25 0
S. aureus 15 14 11 18 13 10 15 17 12 10 13 14 22 23 17 24 0
E. coli 16 12 17 16 20 14 16 15 13 16 14 18 21 21 23 19 0
P. vulgaris 11 13 12 10 12 15 14 13 11 17 10 13 15 18 17 20 0
A.niger 17 15 19 16 18 16 17 18 17 21 17 18 0 0 0 0 25












GRAPHICAL CHART NO. 3 :  1,N-ACETYL-3-ARYL-5-(1’,N-PHENYL-3’-p-BROMOPHENYL-PYRAZOL-4’-YL)-
PYRAZOLINES
COMPARATIVE STUDY OF ANTIMICROBIAL ACTIVITY WITH KNOWN ANTIBIOTICS
[A]
Section - III : Antimicrobial activity of 1,N-Acetyl-3-aryl-5-(1’,N-phenyl-3’-p-bromophenyl-pyrazol-4’-yl)-
pyrazolines
3c (19) 3d (18) 3e (20) 3f (15) 3c (19)
3g (21) 3h (17) 3l (18) 3j (17) 3j (21)
3j (20)
Ampicillin 23 22 21 15 -
Amoxicillin 22 23 21 18 -
Norfloxacin 24 17 23 17 -
Penicillin 25 24 19 20 -
Greseofulvin - - - - 25
B. mega S. aureus E. coli P. vulgaris A. niger
Antifungal activity
Zone of inhibition in m.m.
Antibacterial activity




SYNTHESIS AND BIOLOGICAL EVALUATION OF 1,N-PHENYL-3-
ARYL-5- (1 ' ,N-PHENYL-3 ' -p -BROMOPHENYL-PYRAZOL-4 ' -YL) -
PYRAZOLINES
1-phenyl pyrazolines play a vital role owing of their wide range to
pharmacological activity. In view of these findings, it appeared of interest to
preparing better therapeutic agents, the synthesis of 1,N-phenyl-3-aryl-5-(1',N-
phenyl-3'-p-bromophenyl-pyrazol-4'-yl)-pyrazolines of type (IV) have been
undertaken. The synthesis was carried out by the condensation of chalcone
type (I) with phenyl hydrazine in ethanol.
The constitution of the synthesised products have been characterised using
elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy
and further supported by mass spectrometry. In mass spectrometry the m/z value
indicates the molecular weight, i.e. when R=Phenyl =519, m/z= 519.
The products have been screened for their in vitro biological assay like
antibacterial towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml.
The biological activity of the synthesised compounds have been compared with
standard drugs. Some compounds have been found to have good activity as
compared to  known antibiotics recorded on Graphical Chart No. 4.



























TYPE (IV) R = Aryl
58
IR SPECTRAL STUDY OF 1,N-PHENYL-3-p-BROMOPHENYL-5-(1'-N-PHENYL-3'-p-
BROMOPHENYL-PYRAZOL-4'-YL)-PYRAZOLINE
I
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
 Aromatic C–H str. 3066.6 3080-3030 400
C=C str. 1452.3 1585-1430 ''
C–H i.p.def. 1087.8 1125-1090 "
1010.6 1070-1000 ''
C-H o.o.p. def. 825.5 835-810 "
Pyrazole C=N str. 1643.2 1612-1593 "
C–N str. 1255.6 1420-1020 ''
N-N str. 960.5 1050-1000 "
C-Br str. 561.2 600-500 "
Pyrazoline C=N str. 1643.2 1612-1593 401,403
(overlapped)
N-Ph str. 1492.8 1504-1495 "
C-H str. 2921.9 2900-2880 "






































PMR SPECTRAL STUDY OF 1,N-PHENYL-3-p-METHOXYPHENYL-5-(1',N-PHENYL-
3'-p-BROMOPHENYL-PYRAZOL-4'-YL)-PYRAZOLINE
Internal Standard : TMS
Solvent : CDCl3
Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position J value Relative No. Multiplicity Inference
No. (δ ppm) Hz of Protons
1 3.16 - 1H doublet-doublet Pyrazoline
-CHy
2 3.75 - 1H doublet-doublet Pyrazoline
-CHz
3 3.81 - 3H singlet Ar-OCH3
4 5.47 - 1H doublet-doublet Pyrazoline-CHx
5 6.80 - 1H triplet Ar-H, k
6 7.02 Jfg=9 2H doublet Ar-H, hh'
7 7.08 Jih=7.8 2H doublet Ar-H, ff'
8 7.20 - 3H multiplet Ar-H, n,m,d
9 7.35 - 2H triplet Ar-H, a,b
10 7.47 Jfg=8.4 2H doublet Ar-H, gg'
11 7.55 - 2H doublet Ar-H, l,j
12 7.61 Jhi=7.8 2H doublet Ar- H, ii'
























































































































































































SYNTHESIS AND BIOLOGICAL EVALUATION OF 1,N-PHENYL-3-
ARYL-5- (1 ' ,N-PHENYL-3 ' -p -BROMOPHENYL-PYRAZOL-4 ' -YL) -
PYRAZOLINES
(A) Synthesis of 1-Aryl-3-(1',N-phenyl-3'-p-bromophenyl-pyrazol-4'-yl)-
2-propene-1-ones
See [A] Section-I (C)
(B) Synthesis of 1,N-Phenyl-3-p-methoxyphenyl-5-(1',N-phenyl-3'-p-
bromophenyl-pyrazol-4'-yl)-pyrazolines
A mixture of 1-p-methoxyphenyl-3-(1',N-phenyl-3'-p-bromophenyl-pyrazol-
4'-yl)-2-propene-1-ones (4.59g, 0.01M) and phenyl hydrazine (1.08 g, 0.01M)
in ethanol (20ml) was refluxed for 10 hrs. The resulting mixture was concentrated
and cooled. The product was isolated and crystallised from ethanol. Yield 3.62g,
66%, m.p. 137oC. (C31H25BrN4O; required : C, 67.76; H, 4.59; N, 11.91;
found; C, 67.73;  H, 4.57; N, 11.89%).
TLC Solvent System : Acetone : Benzene (4 : 6)
Similarly other 1-phenyl pyrazolines were synthesised. The physical data
are recorded in Table No. 4.
(C) Antimicrobial activity of 1,N-Phenyl-3-aryl-5-(1',N-phenyl-3'-p-
bromophenyl-pyrazol-4'-yl)-pyrazolines
Antimicrobial testing was carried out as described in [A] Section-I(D). The
zone of inhibition of test solutions are recorded in Graphical Chart No. 4.
65
4a C6H5- C30H23BrN4 519 193 0.543 71 12.72 12.70
4b 4-Br-C6H4- C30H22Br2N4 598 160 0.729 84 10.79 10.75
4c 4-Cl-C6H4- C30H22BrClN4 554 128 0.853 79 11.80 11.77
4d 4-F-C6H4- C30H22BrFN4 537 178 0.681 63 12.22 12.21
4e 4-NH2-C6H4- C30H24BrN5 534 174 0.787 68 15.37 15.35
4f 3-NH2-C6H4- C30H24BrN5 534 188 0.771 80 15.37 15.33
4g 4-NO2-C6H4- C30H22BrN5O2 564 134 0.639 77 14.42 14.38
4h 3-NO2-C6H4- C30H22BrN5O2 564 212 0.539 64 14.42 14.40
4i 4-CH3-C6H4- C31H25BrN4 533 144 0.746 73 12.33 12.29
4j 4-OCH3-C6H4- C31H25BrN4O 549 137 0.813 66 11.91 11.89
4k 4-OH-C6H4- C30H23BrN4O 535 219 0.693 85 12.27 12.26





















































B. mega 15 18 17 19 14 20 17 15 19 16 17 21 23 22 24 25 0
S. aureus 13 16 12 17 11 14 16 15 18 12 13 15 22 23 17 24 0
E. coli 17 15 14 16 18 19 18 17 16 12 13 20 21 21 23 19 0
P. vulgaris 14 13 17 11 13 12 14 10 12 16 14 12 15 18 17 20 0
A.niger 18 14 16 18 17 19 15 17 18 15 18 21 0 0 0 0 25

















COMPARATIVE STUDY OF ANTIMICROBIAL ACTIVITY WITH KNOWN ANTIBIOTICS
[A]
Section - IV : Antimicrobial activity of 1,N-Phenyl-3-aryl-5-(1’,N-phenyl-3’-p-bromophenyl-pyrazol-4’-yl)-
pyrazolines
4f (20) 4d (17) 4e (18) 4c (17) 4f (19)
4l (21) 4i (18) 4f (19) 4j (16) 4l (21)
4g (18)
4l (20)
Ampicillin 23 22 21 15 -
Amoxicillin 22 23 21 18 -
Norfloxacin 24 17 23 17 -
Penicillin 25 24 19 20 -
Greseofulvin - - - - 25
B. mega S. aureus E. coli P. vulgaris A. niger
Antifungal activity
Zone of inhibition in m.m.
Antibacterial activity




The chemistry of triazole derivatives have attained greater interest because
of its useful application in medicine, agriculture and industrial chemistry. Triazoles
contains three nitrogen atom in five membered ring system. Triazoles are of two
types 1,2,4 triazole (I) and 1,2,3-triazole (II).
The chemistry of 1,2,4-triazoles deal briefly in the earlier publications50,51.
The first 1,2,4-triazole derivatives was synthesised by Bladin in 1885. 1,2,4-
triazole derivatives are also used as analytical reagents52, photographic
chemicals53 and in polymer54 synthesis.
SYNTHETIC ASPECT
Several methods have been reported in the literatures for the preparation
of 1,2,4-triazoles. Some procedures for synthesising 1,2,4-triazoles have been
described as under.
1. Reid and Heindel55 reported that the reaction of aryl acid hydrazide with




























2. B. J. Rai & co-workers56 synthesised 3-amino-5-aryl-2-phenyl-2H-1,2,4-
triazole by reaction of aroyl-cyanide with phenyl hydrazine.
3. Versilov and co-workers57 synthesised substituted 1,2,4-triazolyl-5-
amines and 5-thiols by intramolecular cyclisation of R-CO-NH-NH-CX-NH2
(X = NH, S).
4. Zhang Zivi et al.58 prepared 1,2,4-triazoles by the addition reaction of
2 ,4-d ich lorophenoxy ace t icac id  hydraz ide  wi th  R-CO-NCS gave
aroylthiosemicarbazides, cyclization of this in H2O in the presence of
alkaline catalyst gives triazoles.
5. Yassin & co-workers59 synthesised new triazoles via conversion of 1-[α-








R = C6H13, C3F7O,C3F6O,CF(CF)3



























6. Yan  Shiquaing60 prepared by the treatment of ferrocenecarboxylic acid
hydrazide with aryl isothiocyanate produced substituted thiosemicarbazides
which on cyclization gave 3,4-disubstituted-4H-1,2,4-triazole-5-thiol.
7. Shin-ichi Nagai61 synthesised by the reaction of thiosemicarbazide with
formic acid in presence of acetic anhydride (AC2O).
8. Kee-Jung Lee et al.62 prepared 1,2,4-triazole from the electrocyclic reaction
of conjugated heterocumulenes.
9. Chande et al.63 prepared 4-anilino-5-mercapto-S-triazoles from β-acyl
dithiocarbazinate and phenyl hydrazine at 140-160oC.
THERAPEUTIC IMPORTANCE
1,2,4-Triazole derivatives have been reported to be associated with diverse
biological activities. Drug molecules having 1,2,4-triazole nucleus with good










































1. Itraconazole 2. Rilmazafone
3. Diniconazole 4. Rifavirin






















































Plantgrowth regulator Plantgrowth regulator
72
7. Terconazole
8. Fluconazole 9. Amitrole
10. Brotizolam 11. Bitertanol

























































Literature survey reveals that various 1,2,4-triazole derivative have resulted
in many potential drugs and are known to exhibit a broad spectrum of biological
activities. 3-Amino-1,2,4-triazole was the first triazole manufactured on large
scale from aminoguinidine formate useful as neutral herbicides64. Therapeutic

































12. Anticancer and anti-HIV76
13. Plant growth regulator77
14. Antileishmanial78
15. Antitumor79
16. Antidepressant and Anxiolytic80
1,2,4-triazole derivatives have been used successfully in the control of fungal
infection81 and also as nematicidal82, eosinophilia83 inhibitors hypoglycemic
activity84 and microbicides85 for plant protection.
Varvaresou Athanasia and co-workers86 have been synthesised indoyl-
1,2,4-triazole and reported them as antidepressant and antimicrobial agents.
Tsukada Takuo et al.87 have  screened triazoles for their in vivo and in vitro
antifungal activity. Baba Atsuo et al.88 suggested triazole useful as antiheumatic
agents .  L addi  U.  V.  and co-workers89  have prepared t r iazo les  for
anitinflammatory activity, ulcerogenic liability, antimicrobial and antituberculosis
agents. Sun-Qingyan et al.90 have synthesised triazole (X) and reported their
antifungal activity.
Amir  Mohammad91 have prepared 1 ,2 ,4- t r iazo le  der iva t ives  as
ant i inf lammatory agents.  Rama Nasim et  a l .92 documented  In Vitro
antimicrobial activity of 2,4-dihydro-4-benzyl-5-(isomeric pyridyl)-3H-1,2,4-
triazol-3-thiones. Shi, Yan-Nian and co-workers93 have prepared 2H, pyrazolo-










triazolyl-2-indole carboxamides useful as eck-A agonists. Lattmann Rene et al.95
have synthesised 3,5-bis-hydroxy phenyl-1,2,4-tr iazoles (XI) useful  as
pharmaceutical chelators.
Some novel 1H, 1,2,4-triazole derivatives possesing antivirial (antiinfluenza
virus), antibacterial and antifungal agents synthesised by Sproula et al.96 Jag
Mohan et al.97 have synthesised thiazolo-triazoles and studied their antimicrobial
activity. Abdelal Ali et al.98 have investigated some 1,2,4-triazole derivatives as
potential antitumor agents. Rollas Sevim et al.99 have screened 1,2,4-triazoles
as antimicrobial and anticonvulsant agents. El. sayed et al.100 have reported
triazoles (XII) as potent fungicides and bactericides.
Slawinski101 have prepared triazole indicates the potent cardiovascular
agent. A number of 1H-1,2,4-triazole102-105 derivatives have been reported
for  thei r  broad spect rum of  b io logc ia l  ac t iv i t ies ,  some of  them were
commerciallized as agrochemical, fungicides, insecticides, herbicides and plant
growth regulators.
Cesur et al.106 have been reported 1,2,4-triazoles as 100% inhibitor of





















inhibiting cholesteryl ester transfer protein activity. Tsuboi et al.108 have
investigated (XIII) triazole useful for the treatment of autoimmune disease,
inflammation and also for adjuvant Arthritis inhibitors.
Rossi Carla109 have investigated 1,2,4-triazoles having antigestative
immunosuppressant and antitumor activity. Michael et al.110 have reported
triazoles as potential antibacterial agents. Mikail H. et al.111 have documented
triazole as antimicrobial agents. 1,2,4-triazole have been reported for their
pharmacological activity112 and antifungal activity.113 Liu Chanjian et al.114
have investigated triazoles (XIV) as IMPDH inhibitors.
Mari Makoto et al.115 have prepared water soluble triazoles as fungicides.
Laddawahetty et al.116 have synthesised triazoles as selective human GABA
receptor for the treatment of anxiety and enhacing cognition. Giorgia pastorin
et al.117 have documented 1,2,4-triazoles as adenosine recepter antagonist and
also as human A3 and A2B adenosine receptor. B. Shivarama Holla et al.118
have screened 1,2,4-triazoles as anticancer. Uesaka et al. 119 documented
triazoles as adrenergic α2C  receptor antagonists. Biologically active triazole
(XV) were reported by Chepal P. V. et al.120 Aoki Satosh et al.121 have



















These valid observations led us to synthesise several derivatives like aryl
amides, 1,3,4-thiadiazoles, 1,3,4-thiadiazepines having 1,2,4-triazole nucleus
and other 4-aryl triazoles, in order to achieving better therapeutic agents. The
study is described as under.
[B] STUDIES ON TRIAZOLES
PART-I : SYNTHESIS AND BIOLOGICAL EVALUATION OF
ARYLAMIDES
PART-II : SYNTHESIS AND BIOLOGICAL EVALUATION OF 1,3,4-
THIADIAZOLO TRIAZOLES
PART-III : SYNTHESIS AND BIOLOGICAL EVALUATION OF 4-
ARYLTRIAZOLES



















The characteristic group present in the simple carboxylic amide is-CONH2.
They are the acyl substitution products of ammonia. Many natural products are
amides, urea, diamides of carbonic acid. The peptides and proteins are linear
structure of cyclic polyamides. The alkaloids of pepper, piperidine and chavicine
are N-substituted amides of unsaturated acid. N-isobutyl amides of certain highly
usaturated aliphatic acids occur in plants, shows insecticidal activity122. Amides
derived from polyacetylenic acid have been isolated from certain fungi.123
SYNTHETIC ASPECT
Various methods for the synthesis of aryl acetamides are described in
literature.124-129























Amide and substituted amides have widely been used as pharmacologically
useful entities. Some arsano organometallic compounds like tryparsamide and
arsacetin having amide groups have proved to be successful chemotherapeutic













12. Sodium channel blockers144
A. K. Mallams145 has reported arylamide derivatives as antitumor agent.
More over  S. J. Laulloo et al146. and J. Hazarika147 have prepared some
novel  bio logical ly  act ive ary lamide der ivat ives and repor ted them as
antimicrobial agents. Dhanak Dushyant et al.148 have synthesised arylamide













Sanderson Philip E. J. et al149. have synthesised aryl amides and studied
their biological activity. Moloney et al.150 have reported aryl amide derivatives
as antiulcer agents. Foster James et al.151 have synthesised some new amide
derivatives as potent anticonvulsant. Mulik et al.152 have studied some aryl
amides shows antibiotic activity. Bridge Gory153 et al. have  screened arylamides
as anti-HIV agent. Laura and co-workers154 have prepared arylamides as
antibacterial agents. Hobbs et al.155 have designed some amides (III) and
reported them as MCH-receptor antagonist.
Tabuchi et al.156 have screened arylamide derivatives as novel potent
antagonist of human neuropeptide YY5 receptor. Chan
157 have recorded
subst i tu ted benzophenone ary lamide der ivat ives  as  inhib i tor  reverse
transcriptase. Pieters et al.158 have synthesised novel diazene carboxamides
(IV) as anticancer. Anthony and co-workers159 have investigated amides as



























CONTRIBUTION FROM OUR LABORATORY
Some new acetamide derivatives bearing benzimidazol (VI) moiety were
assessed by H. Parekh et al.161 for antimicrobial activity. Parikh et al.162-165
have synthesised novel acetamide derivatives of type (VII), (VIII) and reported
them as antimicrobial agents. Parekh et al.166 have screened amides (IX) as
potent antimicrobial agents.
Some arylamide having quinolone moiety have been reported by A. R.
Parikh et al.167
James B. and co-workers.168 have screened arylamides as selective opioid-
K receptor antagonist. Fanrong mu et al.169 have demostrate novel arylamide
(X) as anticancer. Bin Ho et al.170 have investigated arylamide derivatives (XI)
as anticonvulsant agent. Cudahy et al.171 have prepared arylamide (XII) and






























In the past years, considerable evidence have been accumulated to
demonstrate the pharmacodynamic and chemotherapeutic activities of amide
derivatives. To further assess the potential of such type of compounds, the
synthesis have been carried out which have been described as under.


























SYNTHESIS AND BIOLOGICAL EVALUATION OF 3-MERCAPTO-4,N-
AROYLAMINO-5-BENZHYDRYL-1,2,4-TRIAZOLES
With an intension of preparing the compounds possesing better therapeutic
activity, arylamides of type (V) have been synthesised by the condensation of
3-mercapto-4,N-amino-5-benzhydryl-1,2,4-triazole with different acid chloride.
The constitution of the synthesised products have been characterised using
elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy
and further supported by mass spectrometry. In mass spectrometry the m/z value
indicated the molecular weight, i.e. when R=N,N-dimethyl =353, m/z= 354
(m+1).
All the compounds have been screened for their antibacterial activity
towards Gram positive and Gram negative bacterial strains and antifungal activity
towards Aspergillus niger at a concentration of 40 µg/ml. The biological activity
of the synthesised compounds have been compared with standard drugs. Some
compounds have been found to have moderate activity as compared to known









R = Alkyl/ Aryl
84
REACTION SCHEME
































IR SPECTRAL STUDY OF 3-MERCAPTO-4,N-(N,N-DIMETHYLAMINO CARBONYL
AMINO)-5-BENZHYDRYL-1,2,4-TRIAZOLE
I
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C-H str. (asym.) 2985.6 2975-2950 399
-CH3 C–H str. (sym.) 2875.7 2880-2860 ''
C–H i.p. def. 1475.4 1470-1435 ''
C-H o.o.p. def. 1369.4 1395-1370 ''
C-C str. 1606.6 1680-1620 "
 Aromatic C-H str. 3062.7 3080-3030 435
C=C str. 1510.2 1585-1480 ''
C–H i.p.def. 1091.6 1125-1000 404
C-H o.o.p.def. 816.8 835-810 "
Triazole S-H str. 2424.4 2500-2400 405
C=N str. 1606.6 1650-1580 "
(overlapped)
N- N str. 1022.2 1050-1010 404
C-N str. 1238.2 1220-1020 405
C-S str. 667.3 700-600 "
Amide N-H str. 3219 3300-3100 399
-CO-NH- N-H def. 1587.3 1650-1580 "

























PMR SPECTRAL STUDY OF 3-MERCAPTO-4,N-N,N-DIMETHYLAMINO CARBONYL
AMINO-5-BENZHYDRYL-1,2,4-TRIAZOLES
Internal Standard : TMS
Solvent : CDCl3
Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position J value Relative No. Multiplicity Inference
No. (δ ppm) Hz of Protons
1 2.09 - 1H singlet -SH
2 2.95 - 3H singlet -N-CH3
3 3.12 - 3H singlet -N-CH3
4 5.72 - 1H singlet -CH






















































































































































SYNTHESIS AND BIOLOGICAL EVALUATION OF 1-MERCAPTO-4,N-
AROYLAMINO-5-BENZHYDRYL-1,2,4-TRIAZOLES
(A) Synthesis of Ethyl diphenyl acetate172
A mixture of diphenyl acetic acid (2.12g, 0.01m) in ethanol (20ml) and
conc. H2SO4(1ml) was refluxed for 8hrs. The reaction mixture was poured into
ice cold water. The product was isolated and crystallised from ethanol. Yield
1.8g, 79%, m.p. 59oC
(B) Synthesis of Diphenyl aceto hydrazide173
A mixture of ethyl diphenylacetate (2.4g, 0.01m) in ethanol (20ml) and
hydrazine hydrate (0.5g, 0.01m) was refluxed for 7 hrs. The reaction mixture
was poured into ice cold water. The product was isolated and crystallised from
ethanol. Yield  1.74g, 82%, m.p. 162oC.
(C) Synthesis of Potassium α,α-diphenyl acetamido dithiocarbamate
A mixture of potassium hydroxide (0.56g, 0.01M) in absolute ethanol (25
ml), diphenyl aceto hydrazide (2.26g, 0.01M) and carbon disulfide (1 ml, 0.015M)
was stirred for 15 hrs. The product was precipitated by adding dry ether
(150 ml). Yield 3.12g, 92%.
(D) Synthesis of 3-mercapto-4,N-amino-5-benzhydryl-1,2,4-triazoles
A suspension of  potassium α,α-diphenyl acetamido dithiocarbamate (3.4g,
0.01m), hydrazine hydrate (95%, 1 ml, 0.02M) and water (1 ml) was refluxed
with stirrting for 5 hrs. The content was dilute with water and acidified with
acetic acid to get the product. It was crystallised from DMF/Ethanol. Yield 1.74g,
62%, m.p.  207oC.(C15H14N4S; required : C, 63.80; H, 5.00; N, 19.84; found
: C, 63.76; H, 4.94; N, 19.78%).
TLC Solvent System : Acetone : Benzene  (2 : 8)
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(E) Synthesis of 3-Mercapto-4,N-(N,N-dimethylamino carbonylamino)-
5-benzhydryl-1,2,4-triazoles
A mixture of 3-mercapto-4,N-amino-5-benzhydryl-1,2,4-triazole (2.89g,
0.01M) and N,N-Dimethylamino carbonyl chloride (1.07g, 0.01m) in dry
pyridine (20 ml) was refluxed for 8 hrs. The resulting mixture was poured onto
crushed ice and neutralised with HCl. The product was filtered, washed with
cold water and crystallised from ethanol. Yield 2.54g, 72%, m.p. 134oC.
(C18H19N5OS; required : C, 61.17; H, 5.42; N, 19.81; found : C, 61.14; H,
5.38; N, 19.78%).
TLC Solvent System : Acetone : Benzene  (5 : 5)
Similarly other arylamides were synthesised. The physical data are recorded
in Table No. 5.
(F) Antimicrobial activity of 3-Mercapto-4,N-aroylamino-5-benzhydryl-
1,2,4-triazoles
Antimicrobial testing was carried out as described in [A] Section-I (D). The
zone of inhibition of test solutions are recorded in Graphical Chart No. 5.
93
5a C6H5- C22H18N4OS 386.4 232 0.593 77 14.5 14.2
5b 4-Cl-C6H4- C22H17ClN4OS 421 189 0.708 81 13.31 13.29
5c 2-Cl-C6H4- C22H17ClN4OS 421 198 0.639 68 13.31 13.27
5d 2-F-C6H4- C22H17FN4OS 404.4 149 0.812 55 13.85 18.84
5e -CH3 C17H16N4OS 324.4 117 0.760 74 17.27 17.25
5f -N-(CH3)2 C18H19N5OS 353.4 134 0.663 72 19.81 19.78
5g -N-(C2H5)2 C20H23N5OS 381.49 153 0.728 64 18.36 18.34
5h 4-NO2-C6H4- C22H17N5O3S 431.46 213 0.572 82 16.23 16.20
5i 3,4-di NO2-C6H3- C22H16N6O5S 476.46 234 0.676 55 17.64 17.59
5j 4-CH3-C6H4- C23H20N4OS 400.49 177 0.613 84 13.99 13.94
5k 2-CH3-C6H4- C23H20N4OS 400.49 164 0.792 75 13.99 13.97



























*TLC Solvent System : Acetone : Benzene (5 : 5)
9
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B. mega 18 15 14 16 18 20 19 13 18 21 18 17 23 22 24 25 0
S. aureus 12 14 16 18 13 11 15 10 15 17 14 11 22 23 17 24 0
E. coli 16 18 14 20 14 13 15 17 14 18 20 16 21 21 23 19 0
P. vulgaris 10 12 13 16 15 12 11 10 15 12 13 11 15 18 17 20 0
A.niger 14 18 12 14 19 16 20 16 17 13 21 17 0 0 0 0 25












COMPARATIVE STUDY OF ANTIMICROBIAL ACTIVITY WITH KNOWN ANTIBIOTICS
[B]
PART - I
Section - I : Antimicrobial activity of 3-Mercapto-4,N-aroylamino-5-benzhydryl-1,2,4-triazoles
5f (20) 5c (16) 5b (18) 5d (16) 5g (20)
5g (19) 5d (18) 5d (20) 5e (15) 5k (21)
5j (21) 5j (17) 5j (18) 5i (15)
5k (20)
Ampicillin 23 22 21 15 -
Amoxicillin 22 23 21 18 -
Norfloxacin 24 17 23 17 -
Penicillin 25 24 19 20 -
Greseofulvin - - - - 25
B. mega S. aureus E. coli P. vulgaris A. niger
Antifungal activity
Zone of inhibition in m.m.
Antibacterial activity








1,3,4-Thiadiazole derivatives have been found to be potent drug in
pharmaceutical industries and possess a wide spectrum of biological activity. In
thiadiazole ring system one sulphur and two nitrogen atom present in a five
membered ring. According to their position, thiadiazole system are classified as
1,2,3 thiadiazoles (I), 1,2,4-thiadiazoles (II), 1,3,4-thiadiazoles (III) and 1,2,5-
thiadiazoles (IV).
Fischer was described the first 1,3,4-thiadiazoles in 1882 and fur ther
developed by Busch and co-workers. Due to wide range of therapeutic activities,
the compounds having thiadiazole nucleus have greatly accelerated the rate of
progress in the field of pharmaceutical.
The literature of 1,3,4-thiadiazole have been extensively reviewed by 1947
Sandstrom 174, 1948 Sherman175, 1952 Bambas176, 1977 F. Kurzer177, 1979
M. Devis178, 1979 Campbell.179
SYNTHETIC ASPECT
Literature survey reveals that several publications and patents180 described
the synthesis of 1,3,4-thiadiazoles as under.
1. Kidwai Mazaahir et al.181 have prepared thiadiazole by microwave
irradiation using DMF as an energy transfer medium.


















3. M. K. Albrahim et al.183 have synthesised thiadiazoles from hydrazinyl
chloride.
4. Sun, Xiao-Wen et al.184 and Barghash A. M.185 have synthesised 1,3,4-
thiadiazoles by the cyclisation of acid with triazole in presence of catalyst
like POCl3.
5. 1,3,4-thiadiazolidines have prepared through the intramolecular Mannich





























































6. Jag Mohan et al.187 have prepared thiadiazole derivatives by the cyclization
of amino mercapto triazole and aryl aldehyde in presence of P-Ts-OH.
7. In  1982 Bahadur  e t  a l .188 have prepared th iad iazo le  f rom the
thiosemicarbazides by the cyclization in sulphuric acid.
8. Chande Madhukar  et al.189 have synthesised spiro type 1,3,4-thiadiazole
from amino mercapto triazole.
THERAPEUTIC IMPORTANCE
Extensive research has been carried out to enhance the activity and reduce
toxicity of thiadiazole drugs. Various thiadiazole derivatives have resulted in
many potential drugs and are known to exhibit a broad spectrum of biological
activity.
Miller et al.190 have discovered 1,3,4-thiadiazole-2-sulphonamides and
this compound has been extensively investigated for its effect on salt excretion,
eye pressure and as an anticonvulsant191. R. Gerike192 have prepared
cefazedone (X) is a thiadiazole analog of cephalosporanic acid useful as
antibacterial agent. Recently Kidwai Mazaahir et al.193 have synthesised
cephalosporin derivatives (XI) by microwave irradiation using solid support and




































R' = Me, Et
R = H, Cl
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Wong Zhong-Yi and co-workers194 have synthesised some 3,6-diaryl-5,6-
dihydrotriazolo [3,4-b]- 1,3,4-thiadiazoles (XII) and documented their in vivo
antibacterial and antifungal properties.
Many implications of 1,3,4-thiadiazoles are well proved by a large number
of  patents available on it as therapeutic agents. Thiadiazole derivatives are







































R = 2-OMe, 4-OMe























Jin Fuqliang et al.235 have prepared some novel thiadiazole derivatives
useful as antiulser. Turner Steven et al.236 have synthesised thiadiazoles for
the treatment of CMV infection. Song Yuntao237 have tested thiadiazoles as
cyclooxygenase 2-inhibitors. Some thiadiazole derivatives shown good activity
as anti inf lammatory agents.238,239 El-Sayed et al .240 have repor ted













(XIII) X = O, N, S
1,3,4-Thiadiazolo Triazoles... 101
Severa l  co-worker  have repor ted th iad iazo le  der iva t ives  hav ing
fungicidal,241-244 plant growth regulators245, Insecticidal246, antibacterial247
and metalloproteinase inhibitor248 activity. Karimian et al.249 have prepared
thiadiazole as inhibitors of cysteine activity dependent enzyme. Zhang et al.250
shown antimicrobial activity of thiadiazole derivatives where as Manjunath et
al.251 reported antimicrobial and antiinflammatory activity (XIV).
CONTRIBUTION FROM OUR LABORATORY
Parikh et al. have used substituted thiazolidinone252, benzthiazole and
s-triazine253,254, 4'-pyridyl255 moieties at 5-position (Y) in 1,3,4-thiadiazole
ring system and 2-position (X) was substituted by aryl, amino, and s-triazine256.
H. H. Parekh et al. have synthesised 1,3,4-thiadiazole having dapson257,258
bis moiety, aryl at 5-position (Y) and benzalamino, benzoyl amino and
sulphonamido259, aryl260 moiety substituted at 2-position (X). General structure






















Marc and co-workers261 have investigated thiadiazoles (XVI) as antitumor
agents. Nalan et al.262 reported as anticancer. Pandey V. K. et al.263 have
shown biological activity. Ma, Zhang et al.264 have screened thiadiazoles (XVII)
as fungicides.
Many co-workers  have repor ted 1,3,4- th iadiazo le  der ivat ives  as
antitumor265, nicotinic α7 receptor
266 and antiinflammatory agents.267
In view of the therapeutic activities of 1,3,4-thiadiazoles, it was contemplated
to synthesise 1,3,4-thiadiazolo triazoles in search of agents possesing higher
biological activity with least side effect, which have been described as under.
SECTION-I : SYNTHESIS AND BIOLOGICAL EVALUATION OF 2-
ARYL-4-BENZHYDRYL-1,2,4-TRIAZOLO [3,4-b]-
1,3,4-THIADIAZOLES
SECTION-II : SYNTHESIS AND BIOLOGICAL EVALUATION OF 2-








































(XVI) X, Y = H, F, Cl, Br, I (XVII) R = Aryl
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SECTION - I
SYNTHESIS AND BIOLOGICAL EVALUATION OF 2-ARYL-4-
BENZHYDRYL-1,2,4-TRIAZOLO [3,4-b]-1,3,4-THIADIAZOLES
The study of 1,3,4-thiadiazoles have revealed that thiadiazole derivatives
are valuable drugs for various diseases. These observations led us to synthesise
1,3,4-thiadiazolo triazoles of type (VI) by the cyclisation of 3-mercapto-4,N-
amino-5-benzhydryl-1,2,4-triazole with different aromatic acid in presence of
phosphorous oxychloride.
The constitution of the synthesised compounds have been characterised
using elemental analyses, infrared and 1H nuclear magnetic resonance
spectroscopy and further supported by mass spectrometry. In mass spectrometry
the m/z value indicates the molecular weight, i .e. when R = p-Methyl
phenyl=382, m/z= 383 (m+1).
All the compounds have been screened for their antibacterial activity
towards Gram positive and Gram negative bacterial strains and antifungal activity
towards Aspergillus niger at a concentration of 40 µg/ml. The biological activity
of the synthesised compounds have been compared with standard drugs. Some
compounds have been found to have moderate activity as compared to known































R = ArylType (VI)
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IR SPECTRAL STUDY OF 2-p-METHYLPHENYL-4-BENZHYDRYL-1,2,4-TRIAZOLO
[3,4-b]-1,3,4-THIADIAZOLE
I
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C-H str. (asym.) 2925.8 2975-2950 399
-CH3 C–H str. (sym.) 2837.1 2880-2860 ''
C–H def. (asym.) 1452.3 1470-1435 ''
C-H def. (sym.) 1365.5 1385-1370 ''
C-C- str. 1596.9 1680-1620 "
 Aromatic C-H str. 3008.7 3080-3030 "
C=C str. 1504.4 1585-1430 ''
C–H i.p.def. 1114.8 1125-1090 404
1024.1 1070-1000 "
C-H o.o.p.def. 835.1 835-810 "
Triazole C=N str. 1596.9 1612-1593 399
(overlapped)
C-N str. 1303.8 1360-1310 404
C-N-C str. 1172.6 1146-1132 399
N-N str. 970.1 1050-1010 406





























PMR SPECTRAL STUDY OF 2-p-METHYLPHENYL-4-BENZHYDRYL-1,2,4-TRIAZOLO
[3,4-b]-1,3,4-THIADIAZOLE
Internal Standard : TMS
Solvent : CDCl3
Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position J value Relative No. Multiplicity Inference
No. (δ ppm) Hz of Protons
1 2.43 - 3H singlet Ar-CH3
2 6.04 - 1H singlet -CH
3 7.24-7.36 - 6H multiplet -Ar-H
d,d,d,d,d,d
4 7.35 Hba=7.8 2H doublet -Ar-H, bb'
5 7.43-7.46 - 4H doublet -Ar-H, c,c,c,c.








































































































































































m/z = m/z = m/z = m/z = m/z = 
m/z = 
m/z = 





SYNTHESIS AND BIOLOGICAL EVALUATION OF 2-ARYL-4-
BENZHYDRYL-1,2,4-TRIAZOLO[3,4-b]-1,3,4-THIADIAZOLES
(A) Synthesis of Potassium α,α-diphenyl acetamido dithiocarbamate
See [B] Part - I, Section-I (C)
(B) Synthesis of 3-Mercapto-4,N-amino-5-benzhydryl-1,2,4-triazoles
See [B] Part - I, Section-I (D)
(C) Synthesis of 2-p-Methylphenyl-4-benzhydryl-1,2,4-triazolo [3,4-b]-
1,3,4-thiadiazoles
A mixture of 3-mercapto-4,N-amino-5-benzhydryl-1,2,4-triazole (2.89g,
0.01M) and p-methyl benzoic acid (1.36g, 0.01M) in phosphorous oxychloride
(20 ml) was refluxed for 10 hrs. The resulting mixture was poured onto crushed
ice and neutralised with sodium bicarbonate. The product was filtered, washed
with cold water and crystallised from ethanol. Yield 2.4 g, 63%, m.p. 203oC.
(C23H18N4S : required : C, 72.22; H, 4.74; N, 14.65; found : C,72.20; H,
4.71; N, 14.60%).
TLC Solvent System : Acetone : Benzene (3 : 7)
Similarly other 1,3,4-thiadiazolo triazole derivatives were synthesised. The
physical data are recorded in Table No. 6.
(D) Antimicrobial activity of 2-Aryl-4-benzhydryl-1,2,4-triazolo [3,4-
b]-1,3,4-thiadiazoles
Antimicrobial testing was carried out as described in [A] Section-I (D). The
zone of inhibition of test solutions are recorded in Graphical Chart No. 6.
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6a C6H5- C22H16N4S 368.45 177 0.611 71 15.21 15.19
6b 4-Cl-C6H4- C22H15N4SCl 403 127 0.795 66 13.91 13.86
6c 2-Cl-C6H4- C22H15N4SCl 403 179 0.538 62 13.91 13.90
6d 2-F-C6H4- C22H15FN4S 386.4 144 0.638 58 14.50 14.46
6e 4-OH-C6H4- C22H16N4OS 384.45 138 0.829 63 14.57 14.51
6f 4-NH2-C6H4- C22H17N5S 383.47 118 0.703 74 18.26 18.24
6g 4-NO2-C6H4- C22H15N5O2S 413.45 209 0.558 77 16.94 16.91
6h 3,4-diNO2-C6H3- C22H14N6O4S 458.45 262 0.671 53 18.33 18.29
6i 3-C5H4N- C21H15N5S 369.4 139 0.773 69 18.96 18.94
6j 4-C5H4N- C21H15N5S 369.4 204 0.817 78 18.96 18.91
6k 4-CH3-C6H4- C23H18N4S 382.48 203 0.578 63 14.65 14.60
6l 2-CH3-C6H4- C23H18N4S 382.48 183 0.691 72 14.65 14.63
6m C6H5-CH=CH- C24H18N4S 395 154 0.712 83 14.20 14.19
6n (C6H5)2-CH- C29H22N4S 459 247 0.699 80 12.22 12.20
























































B. mega 12 14 19 16 17 20 17 15 19 17 14 13 20 16 13 23 22 24 25 0
S. aureus 14 12 13 13 18 17 10 15 11 14 15 19 15 14 11 22 23 17 24 0
E. coli 18 14 19 15 16 12 17 12 18 14 12 16 19 12 14 21 21 23 19 0
P. vulgaris 11 12 10 14 16 11 13 12 10 12 14 11 17 10 12 15 18 17 20 0
A.niger 16 17 18 17 19 18 18 14 16 15 20 17 19 18 15 0 0 0 0 25















COMPARATIVE STUDY OF ANTIMICROBIAL ACTIVITY WITH KNOWN ANTIBIOTICS
[B]
PART - II
Section - I : Antimicrobial activity of 2-Aryl-4-benzhydryl-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazoles
6f (20) 6e (18) 6a (18) 6e (16) 6e (19)
6m (20) 6f (17) 6c (19) 6m (17) 6k (20)
6l (19) 6i (18) 6m (19)
6m (19)
Ampicillin 23 22 21 15 -
Amoxicillin 22 23 21 18 -
Norfloxacin 24 17 23 17 -
Penicillin 25 24 19 20 -
Greseofulvin - - - - 25
B. mega S. aureus E. coli P. vulgaris A. niger
Antifungal activity
Zone of inhibition in m.m.
Antibacterial activity





SYNTHESIS AND BIOLOGICAL EVALUATION OF 2-ARYL-4-
BENZHYDRYL-2,3-DIHYDRO-1,2,4-TRIAZOLO [3,4-b] -1 ,3,4-
THIADIAZOLES
1,3,4-Thiadiazole derivatives are associated with broad spectrum of
pharmacological activity. In view of these findings, it appeared of interest to
synthesise newer 1,3,4-thiadiazole derivatives with better potency. 1,3,4-
thiadiazoles of type (VII) have been prepared by the condensation of 3-mercapto-
4,N-amino-5-benzhydryl-1,2,4-triazoles with different aromatic aldehydes in
presence of P-Ts-OH.
The constitution of the synthesised compounds have been characterised
using elemental analyses, infrared and 1H nuclear magnetic resonance
spectroscopy and further supported by mass spectrometry. In mass spectrometry
the m/z value indicates the molecular weight, i .e. when R=p-Methoxy
phenyl= 400, m/z= 401 (m+1).
All the compounds have been screened for their antibacterial activity
towards Gram positive and Gram negative bacterial strains and antifungal activity
towards Aspergillus niger at a concentration of 40 µg/ml. The biological activity
of the synthesised compounds have been compared with standard drugs. Some
compounds have been found to have good activity as compared to known
antibiotics recorded on Graphical Chart No. 7.





































IR SPECTRAL STUDY OF 2-p-METHOXYPHENYL-4-BENZHYDRYL-2,3-DIHYDRO-
1,2,4-TRIAZOLO [3,4-b]-1,3,4-THIADIAZOLE
I
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C-H str. (asym.) 2939.3 2975-2950 399
-CH3 C–H str. (sym.) 2877.6 2880-2860 ''
C–H def. (asym.) 1461.9 1470-1435 ''
C-H def. (sym.) 1342.5 1385-1370 ''
C-C- str. 1602.7 1680-1620 "
 Aromatic C-H str. 3066.6 1380-3030 "
C=C str. 1512.1 1585-1480 ''
C–H i.p. def. 1128.3 1125-1090 "
1070.4 1070-1000 "
C-H o.o.p. def. 831.3 835-810 "
Triazole C= N str. 1602.7 1612-1593 "
(overlapped)
C-N str. 1182.3 1220-1020 405
N-N str. 1028 1050-1010 399
Ether C-O-C str. (asym.) 1249.8 1275-1200 404
C-O-C str. (sym.) 977.8 1075-1020 399
Thiadiazole N-H str. 3319.3 3450-3200 "
N-N str. 1049.2 1050-1010 "
































PMR SPECTRAL STUDY OF 2-p-METHOXYPHENYL-4-BENZHYDRYL-2,3-DIHYDRO-
1,2,4-TRIAZOLO [3,4-b]-1,3,4-THIADIAZOLE
Internal Standard : TMS
Solvent : CDCl3
Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position J value Relative No. Multiplicity Inference
No. (δ ppm) Hz of Protons
1 3.96 - 3H singlet -OCH3
2 5.21 - 1H singlet -CH
3 7.08 Jab=8.4 2H doublet -Ar-H, aa'
4 7.25-7.27 - 4H multiplet -Ar-H, cccc
5 7.31-7.36 - 7H multiplet -Ar-H, dddddd
+-CH- of ring
6 7.93 Jba=8.4 2H doublet -Ar-H, bb'


































7k 4-OH, 3-OCH3-C6H3- 1620.9
7l 3,4 di-OCH3-C6H3- 1616.2
Sr.















































































































SYNTHESIS AND BIOLOGICAL EVALUATION OF 2-ARYL-4-
BENZHYDRYL-2,3-DIHYDRO-1,2,4-TRIAZOLO [3,4-b] -1 ,3,4-
THIADIAZOLES
(A) Synthesis of Potassium α,α-diphenyl acetamido dithocarbamate
See [B] Part-I, Section-I (C)
(B) Synthesis of 3-Mercapto-4,N-amino-5-benzhydryl-1,2,4-triazoles
See [B] Part-I, Section-I (D)
(C) Synthesis of 2-p-Methoxyphenyl-4-benzhydryl-2,3-dihydro-1,2,4-
triazolo [3,4-b]-1,3,4-thiadiazoles
A mixture of 3-mercapto-4,N-amino-5-benzhydryl-1,2,4-triazole (2.89g,
0.01M), p-anisaldehyde (1.36g, 0.01M) in dry DMF (20 ml) and p-toluene
sulphonic acid (50mg) was refluxed for 12 hrs. The reaction mixture was poured
onto crushed ice. The product was isolated and crystallised from ethanol. Yield
2.76g,  69%, m.p. 146oC. (C23H20N4OS : required : C, 68.98; H, 5.03; N,
13.99 found : C, 68.94; H, 5.01; N, 13.97%).
TLC Solvent System : Acetone : Benzene (4 : 6)
Similarly other derivatives were synthesised. The physical data are recorded
in Table No. 7.
(D) Antimicrobial activity of 2-Aryl-4-benzhydryl-2,3-dihydro-1,2,4-
triazolo [3,4-b]-1,3,4-thiadiazoles
Antimicrobial testing was carried out as described in [A] Section-I (D). The
zone of inhibition of test solutions are recorded in Graphical Chart No. 7.
124
7a C6H5- C22H18N4S 370 164 0.811 79 15.12 15.08
7b 4-Cl-C6H4- C22H17ClN4S 405 187 0.628 62 13.84 13.81
7c 2-Cl-C6H4- C22H17ClN4S 405 139 0.776 54 13.84 13.79
7d 4-OH-C6H4- C22H18N4OS 386 253 0.593 72 14.50 14.47
7e 2-OH-C6H4- C22H18N4OS 386 121 0.680 60 14.50 14.49
7f C4H3O- C20H16N4OS 360 152 0.837 58 15.54 15.50
7g 3-NO2-C6H4- C22H17N5O2S 415 135 0.803 65 16.86 16.84
7h 2-NO2-C6H4- C22H17N5O2S 415 198 0.512 73 16.86 16.81
7i 4-OCH3-C6H4- C23H20N4OS 400 146 0.724 69 13.99 13.97
7j C6H5-CH=CH- C24H20N4S 397 193 0.695 83 14.13 14.10
7k 4-OH-3-OCH3-C6H3- C23H20N4O2S 416 177 0.559 77 13.45 13.41























































B. mega 15 11 18 13 17 20 19 16 21 14 18 17 23 22 24 25 0
S. aureus 14 15 12 14 15 12 17 14 18 11 10 13 22 23 17 24 0
E. coli 12 18 15 14 16 17 19 20 17 12 16 14 21 21 23 19 0
P. vulgaris 12 10 14 11 13 17 15 10 18 11 10 13 15 18 17 20 0
A.niger 19 12 16 14 15 18 13 21 14 12 18 15 0 0 0 0 25
















COMPARATIVE STUDY OF ANTIMICROBIAL ACTIVITY WITH KNOWN ANTIBIOTICS
[B]
PART - II
Section - II : Antimicrobial activity of 2-Aryl-4-benzhydryl-2,3-dihydro-1,2,4-triazolo[3,4-b]-1,3,4-
thiadiazoles
7f (20) 7b (18) 7b (18) 7f (17) 7a (19)
7g (19) 7g (19) 7g (19) 7g (15) 7h (21)
7i (21) 7i (17) 7h (20) 7i (18)
Ampicillin 23 22 21 15 -
Amoxicillin 22 23 21 18 -
Norfloxacin 24 17 23 17 -
Penicillin 25 24 19 20 -
Greseofulvin - - - - 25
B. mega S. aureus E. coli P. vulgaris A. niger
Antifungal activity
Zone of inhibition in m.m.
Antibacterial activity





Different type of 1,2,4 triazole derivtives shows variety of pharmacological
activities. 4-Aryltriazole ring system consist of three nitrogen atom in a five
member heterocyclic ring at 1,2,4 position, mercapto group remain free at
position 3 and 4th nitrogon atom is substituted with different aryl groups (I).
SYNTHETIC ASPECT
Several methods have been reported in the literature for the prepartion of
4-aryl triazoles.
See[B] studies on triazoles, synthetic aspect
1. By the reaction of acid hydrazide with
(a) Carbon disulphide, Al. KoH under cyclisation with different amine,
hydrazine.
(b) Thiosemicarbazide derivatives followed by ring closure with NaOH.
THERAPEUTIC IMPORTANCE
4-Aryltriazoles have attracted considerable attention as they appeared of
interest to possess wide range of therapeutic activities. Different activity of 1,2,4-
triazoles already discussed in [B] studies on triazole, therapeutic importance.
Further more chambers et al.268 have investigated 4-aryltriazoles useful
in the treatment of neurogenerative disease. Pler et al.269 reported as irreversible
antagonist at the human A3, A2A adenosine receptor.
270 Patel K. D. et al.271






(I) R = Aryl
128
Many co-worker have reported 4-aryltriazoles as aromatase-steroid sulfatase
inh ib i tors272,  GSK-3 inh ib i tors273,  ant i cancer274,  fung ic ida l275,
antibacterial276, antiinflammatory277, PKB (Protein kinase B) inhibitors278,
Herbicidal279-281 agents.
Recent ly Galcera  et  a l .282 have screened 4-aryl t r iazoles ( I I I )  as
somatostatin receptors. Other co-workers have studied activity of triazoles like
adenosine receptor antagonists283,284,  anticancer285, analgesic and
diuretics286 and in the treatment of diseases  due to excess of metal287 in
body. Heindel and co-workers288 have synthesised 4-aryltriazoles (IV) useful
as Nitric oxide synthatase inhibitors.
With an aim to synthesised better therapeutic agents, we have synthesised
some new 4-aryltriazole derivatives, which have been described as under.
SECTION-I : SYNTHESIS AND BIOLOGICAL EVALUATION OF 3-
MERCAPTO-4,N-ARYL-5-BENZHYDRYL-1,2,4-
TRIAZOLES



























SYNTHESIS AND BIOLOGICAL EVALUATION OF 3-MERCAPTO-4,N-
ARYL-5-BENZHYDRYL-1,2,4-TRIAZOLES
The growing potent literature of recent years demonstrates that the triazole
derivatives are useful as better therapeutic agents. These findings prompted us
to synthesise 3-mercapto-4,N-aryl-5-benzhydryl-1,2,4-triazoles. The synthesise
of triazole derivatives type (VIII) have been under taken by heating of potassium
α,α-diphenyl acetamido dithiocarbamate with different aromatic amines.
The constitution of the synthesised compounds have been characterised
using elemental analyses, infrared and 1H nuclear magnetic resonance
spectroscopy and further supported by mass spectrometry. In mass spectrometry
the m/z value indicated the molecular weight, i.e. when R=p-Methylphenyl=357,
m/z= 358 (m+1).
All the compounds have been screened for their antibacterial activity
towards Gram positive and Gram negative bacterial strains and antifungal activity
towards Aspergillus niger at a concentration of 40 µg/ml. The biological activity
of the synthesised compounds have been compared with standard drugs recorded






















Type  (VIII) R =Aryl
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IR SPECTRAL STUDY OF 3-MERCAPTO-4,N-o-METHYLPHENYL-5-BENZHYDRYL-
1,2,4-TRIAZOLE
I
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C-H str. (asym.) 2950.9 2975-2950 399
-CH3 C–H str. (sym.) 2852.5 2880-2860 ''
C–H def (asym.) 1440.7 1470-1435 ''
C-H def. (sym.) 1348.1 1385-1370 ''
C-C str. 1596.9 1680-1620 "
 Aromatic C-H str. 3020.3 3080-3030 404
C=C str. 1542.9 1585-1570 ''
1502.4 1520-1480 "
C–H i.p.def. 1072.3 1125-1090 "
1051.1 1070-1000 "
C-H o.o.p.def. 837 835-810 "
Triazole C=N str. 1596.9 1612-1593 399
(overlapped)
N- Ph str. 1502.4 1504-1495 "
(overlapped)
N-N str. 1010.6 1050-1010 "
C-N str. 1226.6 1220-1020 405
























PMR SPECTRAL STUDY OF 3-MERCAPTO-4,N-p-METHYLPHENYL-5-BENZHYDRYL-
1,2,4-TRIAZOLE
Internal Standard : TMS
Solvent : CDCl3
Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position J value Relative No. Multiplicity Inference
No. (δ ppm) Hz of Protons
1 2.39 - 3H singlet Ar-CH3
2 5.36 - 1H singlet -CH
3 6.88 Hab=8.4 2H doublet Ar-H, aa'
4 7.02-7.06 - 4H multiplet -Ar-H, cccc
5 7.21 Hba=8.4 2H doublet -Ar-H, bb'


























































































































m/z = m/z = m/z = m/z = m/z = 
m/z = 
m/z = 









SYNTHESIS AND BIOLOGICAL EVALUATION OF 3-MERCAPTO-4,N-
ARYL-5-BENZHYDRYL-1,2,4-TRIAZOLES
(A) Synthesis of Potassium α,α- diphenyl acetamido dithiocarbamate
See [B] Part-I, Section-I (C)
(B) Synthesis of 3-Mercapto-4,N-p-methylphenyl-5-benzhydryl-1,2,4-
triazoles.
A mixture of potassium salt (3.4 g, 0.01M) and p-toluidine (1.07g, 0.01M)
was heated till evolution of H2S gas ceased. The product was dissolved in DMF
(20ml) and poured the reaction mixture onto crushed ice. The product was
crystallised from ethanol. Yield 2.89g, 81% m.p. 183oC. (C22H19N3S; required
: C,73.92; H, 5.36; N, 11.75; found: C, 73.88; H, 5.33; N, 11.71%).
TLC Solvent System : Acetone : Benzene (5 : 5)
Similarly other 4-aryltriazoles were synthesised. The physical data are
recorded in Table No. 8
(C) Antimicrobial activity of 3-Mercapto-4,N-aryl-5-benzhydryl-1,2.4-
triazoles
Antimicrobial testing was carried out as described in [A] Section-I, (D).
The zone of inhibition of test solutions are recorded in Graphical Chart No. 8.
138
8a C6H5- C21H17N3S 343 193 0.576 73 12.23 12.20
8b 4-Cl-C6H4- C21H16ClN3S 378 179 0.637 64 11.12 11.09
8c 3-Cl-C6H4- C21H16ClN3S 378 157 0.748 80 11.12 11.07
8d 2-Cl-C6H4- C21H16ClN3S 378 213 0.802 76 11.12 11.11
8e 4-NO2-C6H4- C21H16N4O2S 388 124 0.720 58 14.42 14.38
8f 3-NO2-C6H4- C21H16N4O2S 388 195 0.541 67 14.42 14.36
8g 2-NO2-C6H4- C21H16N4O2S 388 148 0.693 83 14.42 14.40
8h 4-CH3-C6H4- C22H19N3S 357 183 0.749 81 11.75 11.71
8i 2-CH3-C6H4- C22H19N3S 357 136 0.632 77 11.75 11.73
8j 4-OCH3-C6H4- C22H19N3SO 373 219 0.554 60 11.25 11.20
8k 2-OCH3-C6H4- C22H19N3SO 373 177 0.677 71 11.25 11.22





















































B. mega 11 15 18 19 17 21 14 18 17 19 15 23 22 24 25 0
S. aureus 16 11 14 18 18 16 13 10 14 17 15 22 23 17 24 0
E. coli 14 17 16 18 19 17 16 19 20 17 16 21 21 23 19 0
P. vulgaris 11 13 10 11 14 12 13 17 18 14 14 15 18 17 20 0
A.niger 17 13 18 12 20 16 15 18 14 21 19 0 0 0 0 25











GRAPHICAL CHART NO. 8 :  3-MERCAPTO-4,N-ARYL-5-BENZHYDRYL-1,2,4-TRIAZOLES
COMPARATIVE STUDY OF ANTIMICROBIAL ACTIVITY WITH KNOWN ANTIBIOTICS
[B]
PART - III
Section -I : Antimicrobial activity of 3-Mercapto-4,N-aryl-5-benzhydryl-1,2,4-triazoles
8d (19) 8d (18) 8t (18) 8h (17) 8e (20)
8f (21) 8e (18) 8e (19) 8i (18) 8j (21)
8j (19) 8j (17) 8h (19)
8i (20)
Ampicillin 23 22 21 15 -
Amoxicillin 22 23 21 18 -
Norfloxacin 24 17 23 17 -
Penicillin 25 24 19 20 -
Greseofulvin - - - - 25
B. mega S. aureus E. coli P. vulgaris A. niger
Antifungal activity
Zone of inhibition in m.m.
Antibacterial activity





SYNTHESIS AND BIOLOGICAL EVALUATION OF 3-MERCAPTO-4,N-
ARYL-5-BENZHYDRYL-1,2,4-TRIAZOLES
1,2,4-Triazole derivatives are found to possess a variety of biological
activities. With a view to getting better therapeutic agents, some new triazole
derivatives of type (IX) were prepared by the chemoselective heterocyclization
of thiosemicarbazides in presence of NaOH.
The constitution of the synthesised products have been characterised using
elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy
and further supported by mass spectrometry. In mass spectrometry m/z value
indicates the molecular weight, i.e. when R=p-Methoxyphenyl=373, m/z= 374
(m+1).
All the compounds have been screened for their antibacterial activity
towards Gram positive and Gram negative bacterial strains and antifungal activity
towards Aspergillus niger at a concentration of 40 µg/ml. The biological activity
of the synthesised compounds have been compared with standard drugs recorded
on Graphical Chart No. 9.























IR SPECTRAL STUDY OF 3-MERCAPTO-4,N-p-CHLOROPHENYL-5-BENZHYDRYL-
1,2,4-TRIAZOLE
I
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C-C str. 1641.3 1680-1620 399
Aromatic C-H str. 3070.5 3080-3030 404
C=C str. 1583.4 1585-1570 "
1485.1 1520-1480 "
C-H i.p.def. 1124 1125-1090 "
1018.3 1070-1000 "
C-H o.o.p.def. 827.4 835-810 "
C-Cl str. 750.3 800-600 "
Triazole C=N str. 1641.3 1612-1593 399
(overlapped)
N-Ph. str. 1485 1504-1495 "
(overlapped)
N-N Str. 1124 1050-1010 "
C-N str. 1205.4 1220-1020 405


















PMR SPECTRAL STUDY OF 3-MERCAPTO-4,N,p-METHOXYPHENYL-5-BENZHYDRYL-
1,2,4-TRIAZOLE
Internal Standard : TMS
Solvent : CDCl3
Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position J value Relative No. Multiplicity Inference
No. (δ ppm) Hz of Protons
1 3.76 - 3H singlet Ar-OCH3
2 5.74 - 1H singlet -CH
3 6.82 Jab=8.9 2H doublet -Ar-H, bb'
4 7.22-7.34 - 10H multiplet -Ar-H
5 7.44 Jba=8.7 2H doublet -Ar-H, aa'



































































































































SYNTHESIS AND BIOLOGICAL EVALUATION OF 3-MERCAPTO-4,N-
ARYL-5-BENZHYDRYL-1,2,4-TRIAZOLES
(A) Synthesis of N1-Aryl-N4-(α,α'-diphenylaceto)-thiosemicarbazides
See [C] Section-I (C)
(B) Synthesis of 3-Mercapto-4,N-p-methoxyphenyl-5-benzhydryl-1,2,4-
triazoles.
N1-p-methoxyphenyl-N4-(α,α'-diphenylaceto)-thiosemicarbazide (3.91g,
0.01m) in NaOH sol.n (8%, 20ml) was refluxed for 6 hrs. The resulting mixture
was poured onto crushed ice. The product was isolated, filtered and crystallised
from ethanol. Yield 2.68g, 72%, m.p. 123oC. (C22H19N3OS : required :C, 70.75;
H, 5.13; N, 11.25 ; Found : C, 70.73 ; H, 5.10, N, 11.21%).
TLC Solvent System : Acetone : Benzene (5 : 5)
Similarly other triazoles derivatives were synthesised. The physical data
are recorded in Table No. 9.
(C) Antimicrobial activity of 3-Mercapto-4,N-aryl-5-benzhydryl-1,2,4-
triazoles
Antimicrobial testing was carried out as described in [A] Section-I (D). The
zone of inhibition of test solutions are recorded in Graphical Chart No. 9.
150
9a C6H5- C21H17N3S 343 194 0.537 64 12.23 12.20
9b 4-Cl-C6H4- C21H16ClN3S 378 176 0.659 57 11.12 11.08
9c 2-Cl-C6H4- C21H16ClN3S 378 208 0.824 73 11.12 11.09
9d 4-NO2-C6H4- C21H16N4O2S 388 120 0.714 81 14.42 14.37
9e 2-NO2-C6H4- C21H16N4O2S 388 153 0.691 63 14.42 14.39
9f 4-CH3-C6H4- C22H19N3S 357 189 0.738 55 11.75 11.73
9g 2-CH3-C6H4- C22H19N3S 357 132 0.621 79 11.75 11.70
9h 4-OCH3-C6H4- C22H19N3OS 373 213 0.547 72 11.25 11.21






















































B. mega 14 13 20 17 15 12 14 19 11 23 22 24 25 0
S. aureus 13 12 18 16 10 11 12 17 13 22 23 17 24 0
E. coli 10 13 20 19 12 18 11 19 12 21 21 23 19 0
P. vulgaris 11 10 13 12 14 15 10 17 14 15 18 17 20 0
A.niger 15 11 17 19 12 11 15 20 16 0 0 0 0 25










GRAPHICAL CHART NO. 9 :  3-MERCAPTO-4,N-ARYL-5-BENZHYDRYL-1,2,4-TRIAZOLES
COMPARATIVE STUDY OF ANTIMICROBIAL ACTIVITY WITH KNOWN ANTIBIOTICS
[B]
PART - III
Section - II : Antimicrobial activity of 3-Mercapto-4,N-aryl-5-benzhydryl-1,2,4-triazoles
9c (20) 9c (18) 9c (20) 9f (15) 9d (19)
9h (19) 9d (16) 9d (19) 9h (17) 9h (20)
9h (17) 9f (18)
9g (19)
Ampicillin 23 22 21 15 -
Amoxicillin 22 23 21 18 -
Norfloxacin 24 17 23 17 -
Penicillin 25 24 19 20 -
Greseofulvin - - - - 25
B. mega S. aureus E. coli P. vulgaris A. niger
Antifungal activity
Zone of inhibition in m.m.
Antibacterial activity








1,3,4-Thiadiazepine derivatives are studied extensively because it represents
one of the most active class of compounds possesing a wide spectrum of
pharmacological activities. The thiadiazepine ring system have one sulphur atom
and two nitrogen atom at 1,3,4-position (I) in seven membered heterocyclic
ring system.
Many 1,3,4-thiadiazepine derivatives involve in many biological process
and serves as an synthetic drugs. The thiadiazepine derivatives have stimulated
considerable research work in recent years due to their interesting biological
activities.
SYNTHETIC ASPECT
A cosiderable variety of methods are available for the synthesis of
thiadiazepine derivatives in literature.289-291
1. Sandhu S. S. et al.292 have synthesised thiadiazepine derivatives by
condensation of 2,2'-thiodiacetophenones with hydrazine hydrate in
ethylene glycol.
2. 2-Amino-4-phenyl-6H, 7H-1,3,4-thiadiazepin-5-one293 have synthesised














3. Sinegibskaya A. D. and co-workers294 have synthesised by reaction of
4-amino-3-hydrazino-1,2,4-triazoline-5-thione with α- and β-dicarbonyl
compounds, then the treatment of Br-CH2-CO-Ph to afford thidiazepine.
4. Bolos Jordi et al.295 have synthesised assymetric pyrrolo [2,1-b]-1,3,4-
thiadiazepine derivatives.
5. Tiwari Nirupama et al.296 have prepared 1,2,4-triazolo [3,4-b]-1,3,4-













































6. α -ch loro  ary l  hydrazones  wi th  th ioace tamide o f  th ioace tamido
thiobenzamide mixture in refluxed afforded 1,3,4-thiadiazepine.297
7. Balkr ishna Kul luraya298 and co-workers have synthesised 1,3,4-
thiadiazepine from 1,2,4-triazoles with acetylenic ketones and α-bromo
chalcones.



















































Some other different method have also documented in literature.300-303
THERAPEUTIC IMPORTANCE
Literature survey reveals that 1,3,4-thidiazepines derivatives possess









8. Gastrin Receptor antagonists313-315
9. Anticonvulsant316
Srinivasa et al.317 have prepared pyrazolo-[4,3-f]-1,2,4-triazolo [3,4-b]-
1,3,4-thiadiazepines (IX) and reported them as antibacterial, antifungal, analgesic
and antiinflammatory agents. Dandia Anshu et al.318 have synthesised
spiroindoletriazolo thiadiazepine diones as antibacterial agents. Vice Susan F.319
have investigated di-indolo thiadiazepine derivatives as inflammation inhibitors,
neoplasm inhibitors and for psoriasis treatment. Muramatsu Hiromi et al. 320
have shown anticancer activity of thiadiazepines. Artico Marino et al.321 have
synthesised thiadiazepines useful as non-nucleoside reverse transcriptase agents.
Anti-HIV activity of thiadiazepines have reported by Silvestri Romano et al.322
Also Rodgers James et al.323 have reported 1,3,4-thiadiazepines as potent cyclic





















Puodzhyunjte B. A. et al.324 and Nakchmanovich A. S.325 have patented
some new 1,3,4-thiadiazepines as antiinflammatory agents. Swati Sharma and
co-workers326 have prepared thiadiazepine derivatives as possible potential
drugs for cancer metastatics. U. V. Laddi et al.327 have synthesised triazolo-
thiadiazepines (X) and screened their antimicrobial and antituberculosis activity.
Ammar Y. A. et al.328 have investigated triazolo thiadiazepines as antifungal
agents. Rober t J. Cherney and co-workers329-330 have demonstrated
benzothiadiazepines as selective tumor necrosis factor α-converting enzyme
inhibitors. Brukstus et al.331 have synthesised triazolo-1,3,4-thiadiazepines (XI)




























Thus the important role displayed by 1,3,4-thiadiazepine derivatives for
various therapeutic and pharmaceutical activities  prompted us to synthesise
some new 1,3,4-thiadiazepines bearing triazole moiety, in order to achieve
compounds having better drug potential. This study is described as under.
SECTION-I : SYNTHESIS AND BIOLOGICAL EVALUATION OF 5-




SYNTHESIS AND BIOLOGICAL EVALUATION OF 5-BENZHYDRYL-
1,2,4-TRIAZOLO [3,4-b] SUBSTITUTED QUINOLINO [2,3-f]-1,3,4-
THIADIAZEPINES
During the past years, considerable evidence has been accumulated to
demonstrate the efficiency of thiadiazepines in inducing variety of therapeutic
activity. To further assess the potential of such class of compounds as good
therapeutic agents, a series of 1,3,4-thiadiazepines of type (X) have been
synthesised by the condensation of 3-mercapto-4,N-amino-5-benzhydryl-1,2,4-
triazole with substituted 2-chloro-3-formyl-quinolines.
The constitution of the synthesised compounds have been characterised
using elemental analyses, infrared and 1H nuclear magnetic resonance
spectroscopy and further supported by mass spectrometry. In mass spectrometry
m/z value indicates the molecular weight, i.e. when R=6-Methoxy=450,
m/z= 450.
All the compounds have been screened for their antibacterial activity
towards Gram positive and Gram negative bacterial strains and antifungal activity
towards Aspergillus niger at a concentration of 40 µg/ml. The biological activity
of the synthesised compounds have been compared with standard drugs recorded
on Graphical Chart No. 10.





































IR SPECTRAL STUDY OF 5-BENZHYDRYL-1,2,4-TRIAZOLO [3,4-b]-6-METHOXY
QUINOLINO [2,3-f]-1,3,4-THIADIAZEPINE
I
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C-H str. (asym.) 2974 2975-2950 399
-CH3 C–H str. (sym.) 2839 2880-2860 ''
C–H def (asym.) 1454.2 1470-1435 ''
C-H def. (sym.) 1382.9 1385-1370 ''
C-C str. 1612.4 1680-1620 "
 Aromatic C-H str. 3030 3080-3030 ''
C=C str. 1496.7 1520-1480 ''
C–H i.p.def. 1085.8 1125-1090 404
C-H o.o.p.def. 815.8 835-810 399
Triazole C=N str. 1612.4 1640-1500 ''
(overlapped)
C-N str. 1172.6 1220-1020 405
N-N str. 1022.2 1050-1010 404
Ether C-O-C str. (asym.) 1305.7 1275-1200 ''
C-O-C str. (sym.) 960.5 1070-1000 ''
Triadiazepine C-S-C str. 698.2 700-600 405
1259.4 1250-1000 ''























PMR SPECTRAL STUDY OF 5-BENZHYDRYL-1,2,4-TRIAZOLO [3,4-b]-6-METHOXY
QUINOLINO [2,3-f]-1,3,4-THIADIAZEPINE
Internal Standard : TMS
Solvent : CDCl3
Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position J value Relative No. Multiplicity Inference
No. (δ ppm) Hz of Protons
1 3.95 - 3H singlet Ar-OCH3
2 5.72 - 1H singlet -CH
3 7.20 Jdc=2.4 1H doublet Quinoline  d
4 7.24-7.41 - 11H multiplet -Ar-H +
N=CH- of ring
5 7.49-7.53 Jcd=3 1H doublet-doublet Quinoline c
Jcb=9
6 7.94 Jbc=9 1H doublet Quinoline b












































































































































































































m/z = m/z = 
m/z = 
m/z = 






SYNTHESIS AND BIOLOGICAL EVALUATION OF 5-BENZHYDRYL-
1,2,4-TRIAZOLO [3,4-b] SUBSTITUTED QUINOLINO [2,3-f] 1,3,4-
THIADIAZEPINES
(A) Synthesis of Potassium α,α-diphenyl acetamido dithiocarbamate
See [B] Part-I, Section-I (C)
(B) Synthesis of 3-Mercapto-4,N-amino-5-benzhydryl-1,2,4-triazoles
See [B] Part-I, Section-I (D)
(C) Synthesis of Substituted-2-chloro-quinoline-3-carboxaldehydes332
These were prepared by the reaction of substituted acetanilide with DMF
and POCl3 a well known weilsmayerhacck rearrangement.
(D) Synthesis of 5-Benzhydryl-1,2,4-triazolo [3,4-b]-6-methoxy
quinolino [2,3-f] 1,3,4-thiadiazepines
A mixture of 3-mercapto-4,N-amino-5-benzhydryl-1,2,4-triazole (2.82 g,
0.01m), 2-chloro-3-formyl-6-methoxy quinoline (2.07g, 0.01m) in dry DMF
(20ml) and anhydrous K2CO3 (2.09 g) was stirred at 80
oC for 2 hrs. It was
cooled and poured onto crushed ice. The product was isolated and crystallised
from ethanol. Yield 2.83, 63%, m.p. 194oC. (C26H19N5OS; required : C, 69.47
; H, 4.26 ; N, 15.58 ; found : C, 69.43 ; H, 4.23 ; N, 15.57%).
TLC Solvent System : Acetone : Benzene (3 : 7)
Similarly other substituted 1,3,4-thiadiazepines were synthesised. The
physical data are recorded in Table No. 10.
(E) Antimicrobial activity of 5-Benzhydryl-1,2,4-triazolo [3,4-b]
substituted quinolino [2,3-f] 1,3,4-thiadiazepines.
Antimicrobial testing was carried out as described in [A]  Section-I(D). The
zone of inhibition of test solutions are recorded in Graphical Chart No. 10.
169
10a H C25H17N5S 422 157 0.509 75 16.69 16.65
10b 6-Cl C25H16ClN5S 453.9 208 0.732 61 15.43 15.39
10c 7-Cl C25H16ClN5S 453.9 187 0.776 78 15.43 15.38
10d 8-Cl C25H16ClN5S 453.9 132 0.801 59 15.43 15.41
10e 6,7-di-Cl C25H15Cl2N5S 488 214 0.627 54 14.34 14.30
10f 6-CH3 C26H19N5S 434 232 0.734 64 16.15 16.13
10g 7-CH3 C26H19N5S 434 182 0.689 71 16.15 16.10
10h 8-CH3 C26H19N5S 434 139 0.591 73 16.15 16.11
10i 6-OCH3 C26H19N5OS 450 194 0.760 63 15.58 15.57
10j 8-OCH3 C26H19N5OS 450 169 0.648 67 15.58 15.54
























































B. mega 19 16 11 15 14 18 20 17 16 12 23 22 24 25 0
S. aureus 15 14 13 14 16 15 18 15 17 13 22 23 17 24 0
E. coli 12 17 14 16 15 17 19 16 15 12 21 21 23 19 0
P. vulgaris 14 11 12 17 13 11 15 10 12 14 15 18 17 20 0
A.niger 17 12 15 14 17 18 20 19 15 18 0 0 0 0 25










COMPARATIVE STUDY OF ANTIMICROBIAL ACTIVITY WITH KNOWN ANTIBIOTICS
[B]
PART - IV
Section - I : Antimicrobial activity of 5-Benzhydryl-1,2,4-triazolo[3,4-b]substituted quinolino[2,3-f]1,3,4-
thiadiazepines
10a (19) 10e (16) 10g (19) 10d (17) 10g (20)
10g (20) 10g (18) 10g (15) 10h (19)
10i (17)
Ampicillin 23 22 21 15 -
Amoxicillin 22 23 21 18 -
Norfloxacin 24 17 23 17 -
Penicillin 25 24 19 20 -
Greseofulvin - - - - 25
B. mega S. aureus E. coli P. vulgaris A. niger
Antifungal activity
Zone of inhibition in m.m.
Antibacterial activity








1,3,4-Oxadiazole is a thermally stable neutra aromatic molecular.333 They
have been known for about 80 years, it is only in the last decade that
investigations in this field have been intensified. This is bacause of large number
of application of 1,3,4-oxadiazoles in the most diverse areas viz drug synthesis,
dye stuff industry, heat resistant materials, heat resistant polymers and
scintillators. Reviews of the relevant literature prior to 1965 are available.334
SYNTHETIC ASPECT
Most 1,3,4-oxadiazoles are best obtained by synthesis from acyclic
precursors. Such reactions are 'one-bond' or 'two-bond' cyclisation. Different
methods for the synthesis have been cited in literature.335-342
1. 1,3,4-oxadiazoles have been prepared by reacting acids with benzoyl
hydrazides in the presence of POCl3.
343
2. 1,3,4-oxadiazoles have been synthesised by reaction of acid chloride and
thiosemicrbazide.344 Orthophosphoric acid or dicyclohexyl carbodimide
can be used as cyclising agents.
3. Ghiran and co-worker345 have prepared acetyl oxadiazolines from Schiff's





















4. Liu Fang-Ming et al.346 have prepared acetyl oxadiazolines from hydrazide.
5. Some acetyl oxadiazoline derivatives have been prepared by Kimberley L.
et al.347
THERAPEUTIC IMPORTANCE
2,5-Disubstituted 1,3,4-oxadiazole derivatives have been tested for various
pharmacological properties, which have been summerised as under.














Many co-worker have synthesised oxadiazoles and reported them as novel
PMO inh ib i tor,365  Microb ic ides ,366 anx io ly t i c  & ant i se ro ton in ,367
antagonist,368 and pesticides.369 Mallur et al.370  have reported antimicrobial
activity of oxadiazole derivatives, while Hewawasam et al.371 have showed
calcium activated potassium channel opener activity. Azziza et al.372 have
documented antibacterial activity of oxadiazoles. B. Shivarama Holla et al.373
have investigated 1,3,4-oxadiazoles (III) as antibacterial agents.
1,3,4-Oxadiazoles... 174
CONTRIBUTION FROM OUR LABORATORY
Parikh et al. have synthesised 1,3,4-oxadiazoles having substitution of aryl
sulphonamido,374 aryl,375 mercapto,376 quinolinyl,377 and amino378 at 2-
position (Y) and 4'-pyridyl, benzenesulphonamido phenyl, di-iodoquinolinoxy
and aryl sulphonamidophenyl at 5-position (X) as antimicrobial agents. H. H.
Parekh and co-workers have prepared 1,3,4-oxadiazoles having substituted
triazine,379 phenyl, sulphonyl,380 2-isopropyl-5'-methyl phenoxy methyl,381
dapson,382 moieties at 5-position (X) and aryl, arylamino, arylsulphonamido,
subst i tuted benzalamino moiet ies at 2-posit ion (Y) and screened their
antimicrobial activity. General Structure for above references are as under.
H. Parekh et al.383-388 have formulated some new oxadiazole as
biologically active agents. New 2,5-di substituted oxadiazoles were synthesised
and assessed for antimicrobial activity by Parikh et al.389 Sulabh Sharma et
al.390 have synthesised some novel oxadiazoles (V) as antiinflammatory agents.
Slassi et al.391 have prepared particularly pyridyl and phenyl substituted 1,2,4-
oxadiazoles useful as metabotropic glatamate receptor antagonists for inhibiting



















Y =NH–SO2–R,    Aryl,   –SH,   –NH2,  –NHCO – R,  –N = CH – R
175
as antiinflammatory agents,392 treating a chemokine mediated disease,393
5-HT1A receptor & serotenin receptor antagonist,
394 and biological active
agents395 (VI).
Recently gell et al.396 have reported oxadiazoles as P38 kinase inhibitor.
Grover et al.397 have investigated 1,3,4-oxadiazoles as antifungal and
antibacterial agents. Li Xinghai and co-worker398 have synthesised oxadiazoles
(VII) and reported them as novel insecticidal agents.
In view of therapeutic activities of 1,3,4-oxadiazoles, it was contemplated
to synthesise some new 1,3,4-oxadiazoles in search of agents possessing higher
biological activity with least side effect, which have been described as under.
SECTION-I : SYNTHESIS AND BIOLOGICAL EVALUATION OF
N 1 - A R Y L - N 4 - ( α , α ' - D I P H E N Y L A C E T O ) -
THIOSEMICARBAZIDES
SECTION-II : SYNTHESIS AND BIOLOGICAL EVALUATION OF 2-
ARYLAMINO-5-(α , α-DIPHENYLMETHYL)-1,3,4-
OXADIAZOLES






























SYNTHESIS AND BIOLOGICAL EVALUATION OF N1-ARYL-N4-(α,α'-
DIPHENYLACETO)-THIOSEMICARBAZIDES
Much interest centres around thiosemicarbazide derivatives because of their
wide variety of pharmacological properties. Hence it was considered worthwhile
to synthesise thiosemicarbazide derivatives of the type (XI) for the better drug
potential.
The thiosemicarbazides were synthesised by condensation of different aryl
isothiocyanates and diphenyl aceto hydrazide in ethanol.
The constitution of the synthesised compounds have been characterised
using elemental analyses, infrared and 1H nuclear magnetic resonance
spectroscopy and further supported by mass spectrometry. In mass spectrometry
m/z value indicated the molecular weight, i.e. when R=p-Methoxyphenyl=391,
m/z= 392 (m+1).
All the compounds have been screened for their antibacterial activity
towards Gram positive and Gram negative bacterial strains and antifungal activity
towards Aspergillus niger at a concentration of 40 µg/ml. The biological activity
of the synthesised compounds have been compared with standard drugs,


























TYPE (XI) R = Aryl
178
IR SPECTRAL STUDY OF N1-p-METHYLPHENYL-N4-(α,α,-DIPHENYLACETO)-
THIOSEMICARBAZIDE
I
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C-H str. (asym.) 2933.5 2975-2950 399
-CH3 C-H str. (sym.) 2854.5 2880-2860 "
C-H def. (asym.) 1448.4 1470-1435 "
C-H def. (sym.) 1390.6 1385-1370 "
C-C str. 1662.5 1680-1620 "
Aromatic C-H str. 3084 3080-3030 404
C=C str. 1550.7 1585-1570 "
1487 1520-1480 "
C-H i.e.def. 1087.8 1125-1090 "
1008.7 1070-1000 "
C-H o.o.p. def. 800.4 835-810 "
C-N str. 1188.1 1420-1020 "
N-N str. 954.7 1050-1010 "
Thiosemi C=O str. 1662.5 1690-1650 399
carbazide (overlapped)
N-H str. 3290.3 3450-3200 404

























PMR SPECTRAL STUDY OF N1-p-METHOXYPHENYL-N4-(α,α'-DIPHENYLACETO)-
THIOSEMICARBAZIDE
Internal Standard : TMS
Solvent : CDCl3
Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position J value Relative No. Multiplicity Inference
No. (δ ppm) Hz of Protons
1 3.77 - 3H singlet -Ar-OCH3
2 5.02 - 1H singlet -CH
3 6.784 Jab=9 2H doublet Ar-H, bb'
4 7.00 Jba=8.7 2H doublet Ar-H, aa'
5 7.20-7.31 - 10H multiplet Ar-H
6 8.36 - 1H singlet -NHz-
7 9.56 - 1H singlet -NHy-

























































































































SYNTHESIS AND BIOLOGICAL EVALUATION OF N1-ARYL-N4-(α,α'-
DIPHENYLACETO)-THIOSEMICARBAZIDES
(A) Synthesis of Ethyl diphenyl acetate
See [B] Part-I, Section-I (A)
(B) Synthesis of Diphenylaceto hydrazide
See [B] Part-I, Section-I (B)
(C) Synthesis of N1-p-Methoxyphenyl-N4-(α , α ' -diphenylaceto)-
thiosemicarbazides
An ethanolic solution of diphenylaceto hydrazide (2.26g, 0.01m) and
p-methoxyphenyl isothiocyanate (1.65g, 0.01m) was refluxed for 4 hrs. The
resulting solution was cooled and poured into ice water. The product was isolated
and crystallised from ethanol. Yield 2.81g, 72%, m.p. 137oC. (C22H21N3O2S;
required : C, 67.50 ; H, 5.41 ; N, 10.73 ; found : C, 67.47; H, 5.39; N, 10.69%).
TLC Solvent System : Acetone : Benzene (4 : 6)
Similarly other subsutituted thiosemicarbazides were synthesised. The
physical data are recorded in Table No. 11.
(D) Antimicrobial activity of 3-N1-Aryl-N4-(α,α ' -diphenylaceto)-
thiosemicarbazies
Antimicrobial testing was carried out as described in [A] Section-I (D). The
zone of inhibition of test solutions are recorded in Graphical Chart No. 11.
185
11a C6H5- C21H19N3OS 361 171 0.638 71 11.63 11.59
11b 4-Cl-C6H4- C21H18ClN3OS 396 154 0.714 65 10.61 10.58
11c 2-Cl-C6H4- C21H18ClN3OS 396 198 0.563 68 10.61 10.56
11d 4-NO2-C6H4- C21H18N4O3S 406 172 0.807 54 13.78 13.74
11e 2-NO2-C6H4- C21H18N4O3S 406 211 0.771 53 13.78 13.77
11f 4-CH3-C6H4- C22H21N3OS 375 162 0.590 77 11.19 11.15
11g 2-CH3-C6H4- C22H21N3OS 375 184 0.628 68 11.19 11.17
11h 4-OCH3-C6H4- C22H21N3O2S 391 137 0.754 72 10.73 10.69
11i 2-OCH3-C6H4- C22H21N3O2S 391 125 0.813 70 10.73 10.71






















































B. mega 11 14 19 13 17 20 14 15 18 23 22 24 25 0
S. aureus 14 15 19 17 15 14 10 13 16 22 23 17 24 0
E. coli 18 16 17 15 13 19 16 14 15 21 21 23 19 0
P. vulgaris 13 11 10 14 13 11 17 12 15 15 18 17 20 0
A.niger 17 12 20 11 12 16 19 17 19 0 0 0 0 25










COMPARATIVE STUDY OF ANTIMICROBIAL ACTIVITY WITH KNOWN ANTIBIOTICS
[C]
Section - I : Antimicrobial activity of N1-Aryl-N4-(α,α’-diphenylaceto)-thiosemicarbazides
11c (19) 11c (19) 11a (18) 11g (17) 11c (20)
11f (20) 11d (17) 11f (19) 11i (15) 11g (19)
11i (16) 11i (19)
Ampicillin 23 22 21 15 -
Amoxicillin 22 23 21 18 -
Norfloxacin 24 17 23 17 -
Penicillin 25 24 19 20 -
Greseofulvin - - - - 25
B. mega S. aureus E. coli P. vulgaris A. niger
Antifungal activity
Zone of inhibition in m.m.
Antibacterial activity





SYNTHESIS AND BIOLOGICAL EVALUATION OF 2-ARYLAMINO-5-
(α,α'-DIPHENYLMETHYL)-1,3,4-OXADIAZOLES
Many oxadiazole derivatives are associated with diversified biological
properties. Hence, it was thought of interest that a oxadiazole ring couple to
diphenylaceto hydrazide moiety, the resulting compounds may possess significant
biological potency. Hence the synthesis of 2-arylamino-5-(α,α'-diphenylmethyl)-
1,3,4-oxadiazole (XII) have been under taken by cyclo condensation of
thiosemicarbazide of type (XI) by the action of NaOH/I2.
The constitution of the synthesised compounds have been characterised
using elemental analyses, infrared and 1H nuclear magnetic resonance
spectroscopy and further supported by mass spectrometry. In mass spectrometry
m/z value indicated the molecular weight, i.e. R=p-Nitrophenyl=373, m/z= 374
(m+1).
All the compounds have been screened for their antibacterial activity
towards Gram positive and Gram negative bacterial strains and antifungal activity
towards Aspergillus niger at a concentration of 40 µg/ml. The biological activity
of the synthesised compounds have been compared with standard drugs,
recorded on Graphical Chart No. 12.




















TYPE (XII) R = Aryl
190
IR SPECTRAL STUDY OF 2-o-METHYLPHENYLAMINO-5-(α,α,'-DIPHENYLMETHYL)
-1,3,4-OXADIAZOLE
I
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C-H str. (asym.) 2922 2975-2950 399
-CH3 C-H str. (sym.) 2852.5 2880-2860 "
C-H i.p. def. 1440.7 1470-1435 "
C-H o.o.p def. 1406.0 1395-1370 "
C-C str. 1596.9 1680-1620 "
Aromatic C-H str. 3020.3 3080-3030 404
C=C str. 1502.4 1585-1480 "
C-H i.p.def. 1051.1 1125-1000 "
C-H o.o.p. def. 837 835-810 "
Oxadiazole C=N str. 1596.9 1650-1580 399
(overlapped)
N-N str. 1010.6 1050-1010 404
C-O-C str. 1072.3 1140-1070 "
Secondary N-H str. 3321.2 3550-3250 399
















PMR SPECTRAL STUDY OF 2-p-METHOXYPHENYLAMINO-5-(α,α'-DIPHENYLMETHYL)-
1,3,4-OXADIAZOLE
Internal Standard : TMS
Solvent : CDCl3
Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position J value Relative No. Multiplicity Inference
No. (δ ppm) Hz of Protons
1 3.77 - 3H singlet -Ar-OCH3
2 5.61 - 1H singlet -CH
3 6.834 Jab=9 2H doublet Ar-H, bb'
4 7.24-7.36 - 10H multiplet Ar-H
5 7.46 Jba=8.7 2H doublet Ar-H, aa'







































































































SYNTHESIS AND BIOLOGICAL EVALUATION OF 2-ARYLAMINO-5-
(α,α'-DIPHENYLMETHYL)-1,3,4-OXADIAZOLES
(A) Synthesis of Ethyl diphenyl acetate
See [B] Part-I, Section-I (A)
(B) Synthesis of Diphenylaceto hydrazide
See [B] Part-I, Section-I (B)
(C) Synthesis of N1-Aryl-N4-(α,α'-diphenylaceto)-thiosemicarbazides
See[C] Section-I (C)
(D) Synthesis of 2-p-Methoxyphenylamino-5-(α,α '-diphenylmethyl)-
1,3,4-oxadiazoles
N1-p-methoxyphenyl-N4-(α,α '-diphenyl acetamido)-thiosemicarbazide
(3.91g, 0.01m) dissolved in minimum quiantity of ethanol and NaOH (8ml, 2N).
A solution of iodine (10%) was added dropwise till the color of Iodine persisted
and reaction mixture was refluxed for 4 hrs. at 80oC. The reaction mixture was
poured onto crushed ice. The isolated product was filtered and crystallised from
ethanol. Yield 2.07g, 58%, m.p. 149oC. (C22H19N3O2; required :C, 73.93; H,
5.36; N, 11.76; found: C, 73.90; H, 5.34; N, 11.73%).
TLC Solvent System : Acetone : Benzene (3 : 7)
Similarly other oxadiazoles were prepared. The physical data are recorded
in Table No. 12.
(E) Antimicrobial activity of 2-Arylamino-5-(α,α'-diphenylmethyl)-
1,3,4-oxadiazoles
Antimicrobial testing was carried out as described in [A] Section-I (D). The
zone of inhibition of test solutions are recorded in Graphical Chart No. 12.
197
12a C6H5- C21H17N3O 327 192 0.599 62 12.84 12.81
12b 4-Cl-C6H4- C21H16ClN3O 362 226 0.732 60 11.61 11.59
12c 2-Cl-C6H4- C21H16ClN3O 362 184 0.801 54 11.61 11.57
12d 4-NO2-C6H4- C21H16N4O3 373 247 0.531 66 15.05 15.01
12e 2-NO2-C6H4- C21H16N4O3 373 231 0.628 71 15.05 15.03
12f 4-CH3-C6H4- C22H19N3O 341 163 0.700 68 12.31 12.29
12g 2-CH3-C6H4- C22H19N3O 341 169 0.639 55 12.31 12.27
12h 4-OCH3-C6H4- C22H19N3O2 357 149 0.791 58 11.76 11.73
12i 2-OCH3-C6H4- C22H19N3O2 357 137 0.658 63 11.76 11.71


















































B. mega 14 18 11 15 17 19 16 13 21 23 22 24 25 0
S. aureus 16 12 15 15 14 16 14 11 18 22 23 17 24 0
E. coli 11 17 14 16 15 19 15 12 17 21 21 23 19 0
P. vulgaris 12 10 13 14 16 13 12 11 16 15 18 17 20 0
A.niger 16 15 19 13 16 20 14 17 16 0 0 0 0 25














COMPARATIVE STUDY OF ANTIMICROBIAL ACTIVITY WITH KNOWN ANTIBIOTICS
[C]
Section - II : Antimicrobial activity of 2-Arylamino-5-(α,α’-diphenylmethyl)-1,3,4-oxadiazoles
12f (19) 12a (16) 12f (19) 12e (16) 12c (19)
12i (21) 12f (16) 12i (16) 12f (20)
12i (18)
Ampicillin 23 22 21 15 -
Amoxicillin 22 23 21 18 -
Norfloxacin 24 17 23 17 -
Penicillin 25 24 19 20 -
Greseofulvin - - - - 25
B. mega S. aureus E. coli P. vulgaris A. niger
Antifungal activity
Zone of inhibition in m.m.
Antibacterial activity





SYNTHESIS AND BIOLOGICAL EVALUATION OF 2-ARYL-5-(α,α '-
DIPHENYLMETHYL)-1,3,4-OXADIAZOLES
1,3,4-oxadiazoles are associated with broad spectrum of pharmacological
activity. In view of these finding, it appeared of interest to synthesise newer
oxadiazole derivatives with better potency. Oxadiazole of type (XIII) have been
prepared by condensation of diphenyl aceto hydrazide with different aromatic
acid in presence of POCl3.
The constitution of the synthesised compounds have been characterised
using elemental analyses, infrared and 1H nuclear magnetic resonance
spectroscopy and further supported by mass spectrometry. In mass spectrometry
m/z value indicates the molecular weight, i.e.when R=p-Methoxyphenyl=342,
m/z= 343 (m+1).
All the compounds have been screened for their antibacterial activity
towards Gram positive and Gram negative bacterial strains and antifungal activity
towards Aspergillus niger at a concentration of 40 µg/ml. The biological activity
of the synthesised compounds have been compared with standard drugs,
recorded on Graphical Chart No. 13.
The synthesised compounds have been screened for their in vitro biological
assay like antitubercular activity towards a strain of Mycobacterium tuberculosis
H37Rv at a concentration of 6.25 µg/ml using Rifampin as standard drug.













IR SPECTRAL STUDY OF 2-p-METHOXYLPHENYL-5-(α,α,'-DIPHENYLMETHYL)-
1,3,4-OXADIAZOLE
I
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C-H str. (asym.) 2923.9 2975-2950 399
-CH3 C-H str. (sym.) 2879 2880-2860 "
C-H i.p. def 1456.2 1470-1435 "
C-H o.o.p def 1382.9 1395-1370 "
C-C str. 1612.4 1680-1620 "
Aromatic C-H str. 3028 3080-3030 404
C=C str. 1496.7 1585-1480 "
C-H i.p.def. 1085.8 1125-1000 "
C-H o.o.p. def. 815 835-810 "
Oxadiazole C=N str. 1612.4 1650-1580 399
N-N str. 1020.3 1050-1010 404
C-O-C str. 1072.6 1140-1070 "
Ether C-O-C str. (asym.) 1259.4 1275-1200 "
















PMR SPECTRAL STUDY OF 2-p-METHOXYPHENYL-5-(α,α'-DIPHENYLMETHYL)-
1,3,4-OXADIAZOLE
Internal Standard : TMS
Solvent : CDCl3
Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position J value Relative No. Multiplicity Inference
No. (δ ppm) Hz of Protons
1 3.85 - 3H singlet -Ar-OCH3
2 5.75 - 1H singlet -CH
3 6.96 Jab=9 2H doublet Ar-H, aa'
4 7.26-7.38 - 10H multiplet Ar-H
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SYNTHESIS AND BIOLOGICAL EVALUATION OF 2-ARYL-5-(α,α '-
DIPHENYLMETHYL)-1,3,4-OXADIAZOLES
(A) Synthesis of Ethyl diphenyl acetate
See [B] Part-I, Section-I (A)
(B) Synthesis of Diphenylaceto hydrazide
See [B] Part-I, Section-I (B)
(C) Synthesis of 2-p-Methoxyphenyl-5-(α,α'-diphenylmethyl)-1,3,4-
oxaidzoles
A mixture of diphenylaceto hydrazide (2.26g, 0.01m) and 4-methoxy
benzoic acid (1.52g, 0.01m) in phosphorous oxychoride (10ml) was refluxed
for 6 hrs. The content was cooled and poured on to crushed ice. It was neutralised
with sodium bicaronzte solution. Product was isolated and crystallised from
ethanol. Yield 1.77g, 52%. m.p. 104oC. (C22H18N2O2  : required : C, 77.17;
H, 5.30; N, 818; found : C, 77.13; H, 5.28; N, 8.16%).
TLC Solvent System : Acetone : Benzene (2 : 8)
Similarly other oxadiazoles were prepared. The physical constants  are
recorded in Table No. 13.
(D) Antimicrobial activity of 2-Aryl-5-(α,α'-diphenylmethyl)-1,3,4-
oxadiazoles.
Antimicrobial testing was carried out as described in [A] Section-I (D). The
zone of inhibition of test solutions are recorded in Graphical Chart No.13.
Antitubercular screening of the compounds of type (VIII) was carried out
by TAACF, Southen Reserch Institute, U.S.A. as described in [A] Section-I (D)
and the percentage of inhibition are recorded in Table No.13a.
209
13a 4-Cl-C6H4- C21H15ClN2O 346.8 >280 0.629 67 8.08 8.04
13b 4-OH-C6H4- C21H16N2O2 328.3 215 0.528 72 8.53 8.50
13c 2-OH-C6H4- C21H16N2O2 328.3 133 0.711 58 8.53 8.49
13d 2-OH,3-NH2-C6H3- C21H17N3O2 343.3 >280 0.693 54 11.61 11.58
13e 2-OH-C10H6- C25H18N2O2 378.4 126 0.389 63 7.4 7.3
13f 1-OH-C10H6- C25H18N2O2 378.4 199 0.840 70 7.4 7.1
13g 4-NH2-C6H4- C21H17N3O 327.3 233 0.539 61 12.84 12.82
13h 3-NH2-C6H4- C21H17N3O 327.3 237 0.662 83 12.84 12.80
13i 2-NH2-C6H4- C21H17N3O 327.3 122 0.424 51 12.84 12.81
13j 4-NO2-C6H4- C21H15N3O3 357.3 141 0.578 66 11.76 11.73
13k 4-CH3-C6H4- C22H18N2O 326.3 117 0.642 60 8.58 8.54
13l 3-CH3-C6H4- C22H18N2O 326.3 106 0.713 73 8.58 8.55
13m 4-OCH3-C6H4- C22H18N2O2 342.3 104 0.380 52 8.18 8.16
13n (C6H5)2-CH- C28H22N2O 402.4 256 0.723 69 6.96 6.92
13o C10-H7-OCH2- C26H20N2O2 392.4 103 0.695 55 7.14 7.11

















































B. mega 17 12 13 15 20 15 12 16 19 14 13 17 19 15 12 23 22 24 25 0
S. aureus 14 16 11 16 17 13 11 15 16 15 16 18 12 14 11 22 23 17 24 0
E. coli 15 14 12 15 19 17 13 13 18 16 14 15 18 16 13 21 21 23 19 0
P. vulgaris 11 12 10 12 14 13 15 13 10 13 11 16 14 13 11 15 18 17 20 0
A.niger 13 16 15 14 17 16 14 12 21 13 16 19 20 17 14 0 0 0 0 25



















COMPARATIVE STUDY OF ANTIMICROBIAL ACTIVITY WITH KNOWN ANTIBIOTICS
[C]
Section - III : Antimicrobial activity of 2-Aryl-5-(α,α’-diphenylmethyl)-1,3,4-oxadiazoles
13e (20) 13e (17) 13e (19) 13g (15) 13i (21)
13i (19) 13l (18) 13i (18) 13l (16) 13l (19)
13m (19) 13m (18) 13m (20)
Ampicillin 23 22 21 15 -
Amoxicillin 22 23 21 18 -
Norfloxacin 24 17 23 17 -
Penicillin 25 24 19 20 -
Greseofulvin - - - - 25
B. mega S. aureus E. coli P. vulgaris A. niger
Antifungal activity
Zone of inhibition in m.m.
Antibacterial activity




TABLE NO.13a: PRIMARY ASSAY OF ANTITUBERCULAR ACTIVITY
TAACF, Southern Research Institute Dr. A. R. Parikh
Primary Assay Summary Report Saurashtra University
Sample Corp Whre,R= Supplier Assay Mtb Mic % comment
ID ID Strain Inhib
162164 DS-2N (C6H5)2-CH- Sau.uni Alamar H37Rv >6.25 73
162158 DS-2G 4-Cl-C6H4- Sau.uni Alamar H37Rv >6.25 68  ''
162151 DS-2 4-OCH3-C6H4- Sau.uni Alamar H37Rv >6.25 44  ''
162319 DS-2A 4-CH3-C6H4- Sau.uni Alamar H37Rv >6.25 36  ''
162159 DS-2H 2-OH-C6H4- Sau.uni Alamar H37Rv >6.25 33  ''
162157 DS-2F 3-NH2-C6H4- Sau.uni Alamar H37Rv >6.25 28  ''
162160 DS-2J 2-NH2-C6H4- Sau.uni Alamar H37Rv >6.25 15  ''
162162 DS-2L C10H7-O-CH2- Sau.uni Alamar H37Rv >6.25 15  ''
162153 DS-2B 3-CH3-C6H4- Sau.uni Alamar H37Rv >6.25 14  ''
162163 DS-2M 1-OH-C10H6- Sau.uni Alamar H37Rv >6.25 13  ''
162161 DS-2K 2-OH-C10H6- Sau.uni Alamar H37Rv >6.25 4  ''
162154 DS-2C 4-OH-C6H4- Sau.uni Alamar H37Rv >6.25 0  ''
162156 DS-2E 4-NH2-C6H4- Sau.uni Alamar H37Rv >6.25 0  ''
NIAID/ Southern Research institute/ GWL Hansen's Center/
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LIST OF
NEW COMPOUNDS
R R
C6H5-
4-Br-C6H4-
4-Cl-C6H4-
4-F-C6H4-
4-NH2-C6H4-
3-NH2-C6H4-
4-NO2-C6H4-
3-NO2-C6H4-
4-CH3-C6H4-
4-OCH3-C6H4-
4-OH-C6H4-
2-OH-C6H4-
C6H5-
4-Br-C6H4-
4-Cl-C6H4-
4-F-C6H4-
4-NH2-C6H4-
3-NH2-C6H4-
4-NO2-C6H4-
3-NO2-C6H4-
4-CH3-C6H4-
4-OCH3-C6H4-
4-OH-C6H4-
2-OH-C6H4-
N
N
Br
NH N
R
N
N
R
O
Br
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R R
C6H5-
4-Br-C6H4-
4-Cl-C6H4-
4-F-C6H4-
4-NH2-C6H4-
3-NH2-C6H4-
4-NO2-C6H4-
3-NO2-C6H4-
4-CH3-C6H4-
4-OCH3-C6H4-
4-OH-C6H4-
2-OH-C6H4-
C6H5-
4-Br-C6H4-
4-Cl-C6H4-
4-F-C6H4-
4-NH2-C6H4-
3-NH2-C6H4-
4-NO2-C6H4-
3-NO2-C6H4-
4-CH3-C6H4-
4-OCH3-C6H4-
4-OH-C6H4-
2-OH-C6H4-
N
N
Br
N N
R
CH3
O
N
N
Br
N N
R
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R R
C6H5-
4-Cl-C6H4-
2-Cl-C6H4-
2-F-C6H4-
-CH3
-N-(CH3)2
-N-(C2H5)2
4-NO2-C6H4-
3,4-di NO2-C6H3-
4-CH3-C6H4-
2-CH3-C6H4-
3-C5H4N-
C6H5-
4-Cl-C6H4-
2-Cl-C6H4-
2-F-C6H4-
4-OH-C6H4-
4-NH2-C6H4-
4-NO2-C6H4-
3,4-diNO2-C6H3-
3-C5H4N-
4-C5H4N-
4-CH3-C6H4-
2-CH3-C6H4-
C6H5-CH=CH-
(C6H5)2-CH-
C10H7-OCH2-
N
N
N
S
N R
N
N
N
SH
NH
O
R
239
R R
C6H5-
4-Cl-C6H4-
2-Cl-C6H4-
4-OH-C6H4-
2-OH-C6H4-
C4H3O-
3-NO2-C6H4-
2-NO2-C6H4-
4-OCH3-C6H4-
C6H5-CH=CH-
4-OH-3-OCH3-C6H3-
3,4-di-OCH3-C6H3-
C6H5-
4-Cl-C6H4-
3-Cl-C6H4-
2-Cl-C6H4-
4-NO2-C6H4-
3-NO2-C6H4-
2-NO2-C6H4-
4-CH3-C6H4-
2-CH3-C6H4-
4-OCH3-C6H4-
2-OCH3-C6H4-
N
N
N
S
N
H
R
N N
N SH
R
240
R R
C6H5-
4-Cl-C6H4-
2-Cl-C6H4-
4-NO2-C6H4-
2-NO2-C6H4-
4-CH3-C6H4-
2-CH3-C6H4-
4-OCH3-C6H4-
2-OCH3-C6H4-
H
6-Cl
7-Cl
8-Cl
6,7-di-Cl
6-CH3
7-CH3
8-CH3
6-OCH3
8-OCH3
N N
N SH
R
N N
N
N
S
N
R
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R R
C6H5-
4-Cl-C6H4-
2-Cl-C6H4-
4-NO2-C6H4-
2-NO2-C6H4-
4-CH3-C6H4-
2-CH3-C6H4-
4-OCH3-C6H4-
2-OCH3-C6H4-
C6H5-
4-Cl-C6H4-
2-Cl-C6H4-
4-NO2-C6H4-
2-NO2-C6H4-
4-CH3-C6H4-
2-CH3-C6H4-
4-OCH3-C6H4-
2-OCH3-C6H4-
O
NH
NH S
NH
R
N N
O NH R
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RN N
O R
4-Cl-C6H4-
4-OH-C6H4-
2-OH-C6H4-
2-OH,3-NH2-C6H3-
2-OH-C10H6-
1-OH-C10H6-
4-NH2-C6H4-
3-NH2-C6H4-
2-NH2-C6H4-
4-NO2-C6H4-
4-CH3-C6H4-
3-CH3-C6H4-
4-OCH3-C6H4-
(C6H5)2-CH-
C10-H7-OCH2-
243
